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Asn  (N) Asparagine 
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Gln (Q) Glutamine 
Glu (E) Glutamic acid 
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Ile (I) Isoleusine 
Leu (L) Leusine 
Lys (K) Lysine 
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Phe (F) Phenylalanine 
Pro (P) Proline 
Ser (S) Serine 
Thr (T) Threonine 
Trp (W) Tryptophan 
Tyr (Y) Tyrosine 
Val (V) Valine 
  
bp base pair 
LC liquid chromatography 
MS mass spectrometry 
NMR nuclear magnetic resonance 
NRPS non-ribosomal peptide synthetase 
PCR polymerase chain reaction 
PRPS post-ribosomal peptide synthesis 
RiPPs ribosomally synthesized post-translationally modified peptides 
patA-G genes encoding patellamide biosynthetic genes  
PatA-G proteins encoded by the pat genes  
sp. species 
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Abstract 
 
Ribosomal peptides are produced through the post-translational 
modification of short precursor peptides. The chemical diversity of ribosomal 
peptides is enormous and they are found in all domains of life. Cyanobactins 
are a new family of ribosomal peptides produced by cyanobacteria. A great 
variety of cyclic peptides that can be assigned to the cyanobactin family are 
described from cyanobacteria or from marine animals that harbour 
cyanobacteria. Most cyanobactins have been found in screening programs to 
identify anti-cancer compounds and the first cyanobactin was reported from 
a marine tunicate in 1980. The biosynthetic origins of cyanobactins remained 
unclear until 2005 when they were shown to be produced through the post-
translation modification of a short precursor peptide by the symbiotic 
cyanobacteria Prochloron. The precursor peptide is cleaved, N-to-C 
macrocyclized, and in some cases the amino acids can be heterocyclized or 
prenylated. As a family, the cyanobactins possess cytotoxicity, multidrug-
resistance reversing activity, anti-malarial, antimicrobial, and allelopathic 
activities.  
 
The aim of this study was to explore the distribution of cyanobactin pathways 
and determine the chemical diversity of the peptides they encode. 
Cyanobacterial strains were studied using a combination of bioinformatics, 
molecular biology, evolutionary biology, and structural chemistry.  
 
A PCR-based approach demonstrated that the cyanobactin genes are 
common and sporadically distributed in bloom-forming cyanobacteria. The 
gene  encoding  the  PatA  protease  was  found  in  48  of  132  cyanobacterial  
strains studied. A cyanobactin gene cluster was detected in the draft genome 
of bloom-forming cyanobacterium Anabaena sp.  90.  The  product  of  the  
pathway was identified as a cyclic peptide, consisting of proteinogenic amino 
acids, and was named anacyclamide. Diverse anacyclamides were identified 
from 27 strains of the genus Anabaena. Anacyclamides are cyclic peptides 
consisting of 7-20 proteinogenic amino acids which were prenylated or 
geranylated in some strains. Genome mining also identified an inactive 
cyanobactin gene cluster in M. aeruginosa NIES843. Based on genetic 
similarity, an active counterpart was found, and this led to the discovery of 
functional cyanobactin gene clusters in 6 strains of the genus Microcystis 
which produced new cyanobactins. These peptides, which were named 
piricyclamides, are similar to anacyclamides. Piricyclamides have 7 to 17 
amino acids and like anacyclamides the only conserved amino acid is a single 
proline.  
 
Bioinformatic analysis of the cyanobactin pathway in 126 cyanobacterial 
genomes identified 31 cyanobactin gene clusters. Surprisingly, two of the 
pathways  identified  in  this  study  were  shown  to  produce  novel  linear  
cyanobactins. These linear peptides contain a thiazole and an N-terminus 
protected  with  a  prenyl  group  and  methylated  C-terminus.  The  linear  
cyanobactins, consisting of just 3-5 amino acids, were named 
aeruginosamides B, C, and viridisamide A. Genome mining demonstrated 
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that cyanobactin pathways were widely distributed among all cyanobacteria. 
Phylogenetic analyses subsequently showed that the cyanobactin pathway 
has a complex evolutionary history which differs from the evolutionary 
history of cyanobacteria.  
 
The cyanobactin family was originally defined as being cyclic peptides 
containing heterocyclized amino acids and/or prenylated amino acids. In this 
study, altogether three types of cyanobactins were described, cyclic 
anacyclamides, piricyclamides, and the linear cyanobactins aeruginosamides 
and viridisamide A. This work broadened the cyanobactin definition to 
include  unmodified  cyclic  peptides,  and  expanded  the  length  variation  of  
cyanobactins setting new upper and lower limits, 3–20, for the length of the 
peptides in the cyanobactin family. The definition of cyanobactin was further 
refined to include linear peptides with termini protected by prenylation and 
methylation. Overall, this study has shown that the cyanobactin pathway is 
common in cyanobacteria and able to produce a range of chemically diverse 
peptides.  
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Tiivistelmä 
 
Bakteerit tuottavat paljon erilaisia pieniä ribosomaalisia peptidejä, jotka on 
tuotettu suuremmasta esipeptidistä muokkaamalla. Ribosomaalisia 
peptidien tuottajia löytyy kaikista eliökunnan kolmesta pääryhmästä. 
Syanobaktiinit ovat syanobakteerien tuottamia ribosomaalisia 
rengaspeptidejä, joita on kuvattu myös merieläimistä, joissa on 
syanobakteereita. Suurin osa syanobaktiineista on löydetty etsittäessä 
lääkeaineita syöpäsoluja vastaan. Ensimmäinen syanobaktiini kuvattiin 
vaippaeläimestä 1980. Syanobaktiinien alkuperä saatiin selville vasta 2005, 
kun biosynteesi kuvattiin vaippaeläimen symbioottisesta Prochloron-
syanobakteerista. Syanobaktiinien biosynteesissä ensin tuotetaan esipeptidi, 
jota muokataan translaation jälkeen. Esipeptidistä katkaistaan lopullisen 
syanobaktiinin muodostava osa, josta muodostetuu rengas, kun 
aminohappoketjun amino- ja karboksyylipää yhdistetään. Joistakin 
syanobaktiinien aminohapoista on muodostettu heterosyklejä tai 
aminohappoja on prenyloitu. Syanobaktiinien on havaittu olevan soluille 
myrkyllisiä, antimikrobisia, lääkevastustuskyvyn alentavia ja malariaa 
vastaan toimivia vaikutuksia sekä niillä on havaittu myös olevan muiden 
eliöiden kasvuun vaikuttavia, allelopaattisia, ominaisuuksia. 
 
Tässä työssä on tutkittu syanobaktiinien biosynteesigeenien esiintymistä 
syanobakteereissa sekä syanobaktiinien kemiallisten rakenteiden 
monimuotoisuutta. Tutkimus tehtiin syanobakteerikantoja tutkimalla ja 
yhdistelemällä bioinformatiikkaa, molekyylibiologiaa, evoluutiobiologiaa 
sekä kemiallisia menetelmiä.  
 
Syanobaktiinien tuottamiseen tarvittavien geenien todettiin olevan yleisiä 
erityisesti massaesiintymiä eli kukintoja muodostavilla syanobakteereilla. 
Tutkituista 132 syanobakteerikannasta 48 löydettiin PCR-menetelmällä 
syanobaktiini biosynteesille oleellinen patA-geeni. Anabaena sp.  90  -
syanobakteerin genomissa oli syanobaktiinien tuottamiseksi tarvittavat 
geenit. Geenien tuottama syanobaktiini löydettiin ja se oli rengaspeptidi, joka 
koostui tavallisista aminohapoista. Tämä uusi syanobaktiini nimettiin 
anasyklamidiksi. Anasyklamideja löydettiin 27 Anabaena-kannasta. 
Anasyklamidit ovat rengaspeptidejä, jotka koostuvat 7–20 tavallisesta 
aminohaposta ja toisinaan jokin aminohappo oli prenyloitu tai geranyloitu. 
Microcystis aeruginosa NIES 843 -kannan genomissa on toimimaton 
syanobaktiini geeniryhmä. Kuudesta Microcystis-kannasta löydettiin 
vastaavanlaisia, mutta toiminnallisia geenejä, jotka tuottivat uudenlaisia 
syanobaktiineja. Peptidit nimettiin pirisyklamideiksi. Pirisyklamideissa on 
7–17 tavallista aminohappoa, joista viimeinen on aina proliini, kuten 
anasyklamideissakin. Myös pirisyklamideissa on prenyloituja tai 
geranyloituja aminohappoja. Joissakin pirisyklamideissa oli myös rikkisilta, 
joka yhdistää kaksi peptidirenkaassa olevaa kysteiiniä toisiinsa.  
 
Bioinformaattisen analyysin avulla löydettiin 126 syanobakteerigenomista 31 
syanobaktiinien tuottamiseen tarvittavaa geeniryhmää. Näistä kahden 
geeniryhmän havaittiin tuottavan lineaarisia syanobaktiineja, joissa on vain 
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3–5 aminohappoa. Näissä lineaarisissa syanobaktiineissa on kysteiinistä 
muokattu heterosyklinen tiatsolirengas, prenyyliryhmällä suojattu aminopää 
sekä metyloitu karboksyylipää. Uudet lineaariset syanobaktiinit nimettiin 
aeruginosamidi B:ksi ja C:ksi sekä viridisamidi A:ksi. Genomeja tutkimalla 
havaittiin, että syanobaktiinien tuottamiseksi tarvittavat geeniryhmät ovat 
laajalle levinneitä syanobakteerien joukossa. Fylogeneettisten analyysien 
avulla osoitettiin, että syanobaktiineja tuottavien geenien evolutiivinen 
historia on monimutkainen ja se eroaa syanobakteerien evolutiivisesta 
historiasta. 
 
Aikaisemmin syanobaktiinit oli määritelty rengaspeptideiksi, joissa on 
heterosyklisiksi muokattuja tai prenyloituja aminohappoja. Tässä työssä 
kuvattiin kolmenlaisia syanobaktiineja; rengasmaiset anasyklamidit ja 
pirisyklamidit sekä lineaariset aeruginosamidit ja viridisamidi A. Työssä 
laajennettiin syanobaktiinien määritelmää käsittämään myös ainoastaan 
tavallisista aminohapoista koostuvia rengaspeptidejä sekä asetettiin uudet 
ääripituudet syanobaktiineille (3–20 aminohappoa). Syanobaktiinit 
määriteltiin nyt sisältämään myös lineaarisia peptidejä, joiden päät on 
suojattu prenyloimalla ja metyloimalla. Kaiken kaikkiaan työ osoitti, että 
syanobaktiinien tuottamiseksi tarvittavat geenit ovat yleisiä 
syanobakteereilla ja ne tuottavat suuren joukon erilaisia syanobaktiineja. 
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1. Introduction 
1.1. Cyanobacteria 
 
Cyanobacteria are aerobic photoautotrophs and require only light, carbon 
dioxide, water, and inorganic substances for growth. Cyanobacterial species 
can occupy terrestrial habitats and, more commonly, aqueous environments. 
They can survive extreme conditions, such as high salinity, high and low 
temperatures,  and  high  levels  of  UV-radiation.  The  morphology  of  
cyanobacteria is diverse with unicellular, colonial, and multicellular 
filamentous forms. Cyanobacteria form a distinct group in the phylogenetic 
tree based on bacterial 16S rRNA genes (Castenholz 2001). They are 
infamous  for  the  production  of  toxins  including  the  most  studied  group  of  
secondary metabolites, the hepatotoxic microcystins (Sivonen and Jones 
1999). Cyanobacteria are also rich in other secondary metabolites, some of 
which have interesting antimicrobial, anti-HIV, and anticancer activities 
(Burja et al. 2001, Welker and von Döhren 2006). The structural diversity of 
cyanobacterial secondary metabolites is tremendous, but their ecological role 
remains unclear (Burja et al. 2001, Welker and von Döhren 2006). 
1.2. Ribosomally synthesized and post-translationally-
modified peptides 
 
Ribosomally synthesized and post-translationally modified peptides (RiPPs) 
are produced in all three domains of life; Archaea, Bacteria and Eucarya 
(Arnison et al. 2013). These peptides are produced by a pathway now 
designated as post-ribosomal peptide synthesis (PRPS), analogous to non-
ribosomal peptide synthetase (NRPS), enzymes that catalyse the biosynthesis 
of peptides by a modular pathway which acts independently of the ribosome 
(Arnison et al. 2013). In PRPS, an unmodified precursor peptide is produced 
by normal translation on the ribosome. This precursor peptide directly 
encodes the sequence that will form the end-product peptide (Figure 1). This 
region  is  termed  the  core  sequence  (Oman  and  van  der  Donk  2010  and  
Arnison  et  al.  2013).  The  precursor  peptide  is  subsequently  cleaved  and  
modified to form the final end-product (Figure 1). A wide range of 
modifications has been described such as various cyclizations and linkages of 
the amino acid backbone, phosphorylation, hydroxylation, carboxylation, 
glycosylation, C-terminal amination, epimerization, lanthionine formation, 
prenylation,  and  heterocyclization  (Arnison  et  al.  2013,  Dunbar  et  al.  2013,  
McIntosh  et  al.  2009).  Examples  of  RiPPs  include  bacterial  lanthipeptides,  
microcins, lasso peptides in actinobacteria and proteobacteria, fungal 
amatoxins and phallotoxins, cyclotides and orbitides in plants, conopeptides 
in snails, and cyanobactins and microviridins in cyanobacteria (Oman and 
van der Donk 2010 and Arnison et al. 2013). RiPPs are mostly known for 
their antibacterial activities but other interesting bioactivities have been 
reported, such as anti-malarial, anticancer, and anti-HIV activities (Arnison 
et al. 2013). The ever increasing number of microbial genome sequences 
promotes the discovery of ribosomally synthesized natural products because 
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the product is directly linked to the precursor gene sequence (Velásques and 
van der Donk 2011). 
 
 
Figure 1. Schematic of post-ribosomal peptide synthesis (PRPS). 
1.3. Cyanobactins 
 
Cyanobactins are small cyclic peptides produced by many cyanobacteria 
(Donia et al. 2008a, Sivonen et al. 2010, Donia and Schmidt 2010). The first 
cyanobactins, ulicyclamides and ulithiacyclamides, were described in a 
tunicate Lissoclinum patella for the first time by Ireland and Scheuer (1980). 
Many cyanobactins are found from marine animals which harbour 
cyanobacteria (Donia and Schmidt 2010, Sivonen et al. 2010). The tunicate L. 
patella has an obligate symbiotic cyanobacterium, Prochloron, and it was 
hypothesised that the symbiont is the producer of the cyanobactins (Sings 
and Rinehart 1996). In fact, two separate but simultaneous studies proved 
that Prochloron synthesizes these metabolites, patellamides, by a PRPS 
pathway (Long et al. 2005, Schmidt et al. 2005). The biosynthetic pathway 
for patellamides was discovered based on genome sequencing of symbiotic 
Prochloron cells followed by heterologous expression (Schmidt et al. 2005) 
and in the concomitant study by shotgun cloning and heterologous 
expression of the clones directly (Long et al. 2005). In both of the studies, the 
PRPS pathway for patellamide biosynthesis from the unculturable 
Prochloron was expressed in a heterologous host demonstrating that 
patellamides  are  made  by  a  PRPS  instead  of  an  NRPS  pathway.  The  name  
cyanobactins was first introduced to this family of peptides by Donia et al. 
(2008a).  
 
1.4. Cyanobactin producers 
 
The vast majority of cyanobactins are described from marine animals, such 
as ascidians and sponges (Table 1), which often harbour cyanobacteria. In the 
ascidian Lissoclinum patella the obligate symbiont Prochloron has been 
proven  to  be  the  producer  of  cyanobactins  (Schmidt  et  al.  2005).  The  
biosynthetic genes have been described in the genome of Prochloron and it is 
highly likely that producers of all these closely related compounds in marine 
organisms (Table 1) are the cyanobacteria harbouring them (Schmidt et al. 
 12 
 
2005,  Donia  and  Schmidt  2010).  Cyanobactins  are  also  frequently  found in  
free-living cyanobacteria from freshwater, oceanic, and terrestrial habitats 
(Table 2). The most frequent free-living producers of cyanobactins seem to 
be the strains of the genera Microcystis and Oscillatoria (Table 2). Based on 
a study of 126 cyanobacterial genomes cyanobactin gene clusters are found in 
10 % of the genomes (Shih et al. 2013). 
 
1.5. Chemical diversity of cyanobactins 
 
The name cyanobactin refers to cyanobacterial, ribosomally-synthesised, 
cyclic peptides which may have prenylated or heterocyclized amino acids 
(Figure 2). Not all compounds that belong structurally to this group of 
peptides are proven to be synthesized by the cyanobactin pathway. Based on 
current knowledge, it is probable that all cyanobactin-like peptides (Tables 1 
and 2) are biosynthetically related (Donia and Schmidt 2010, Sivonen et al. 
2010).  Cyanobactins  consist  of  7  to  20  amino  acids,  which  are  generally  in  
the L-conformation, but D-amino acids are also occasionally found in these 
peptides. D-amino acids are often located next to a heterocyclized amino acid 
(Milne et al. 2006, McIntosh et al. 2009). Epimerisation in the cyanobactins 
is considered to be non-enzymatic (Milne et al. 2006, McIntosh et al. 2009). 
If the cyanobactin encodes a cysteine it is heterocyclized to thiazole or 
thiazoline, or forms di-sulfide bridge with another cysteine. Threonines and 
serines are often heterocyclized to oxazoles or oxazolines. The oxidation level 
of heterocycles varies but it seems that the oxidised forms are more common 
especially considering thiazoles. Sometimes the cyanobactins are prenylated 
or, much more rarely geranylated. The known prenylated amino acids are 
tyrosine, serine, threonine, and tryptophan (Table 1-2). In marine animals 
prenylated cyclic peptides are occasionally reported and these compounds 
are probably made by cyanobacteria. For example, myriastramides have O-
prenylated tyrosine (Erickson et al. 2003) and mollamides have O-prenylated 
serine (Donia et al. 2008b). Some of the cyanobactins have di-sulfide bridges 
from cysteine  to  cysteine.  The  cyanobactin  gene  cluster  does  not  encode  an  
enzyme to carry out the formation of the disulfide bridge and it is most likely 
a spontaneous reaction (McIntosh et al. 2009). Biosynthetic pathways for 
halogenated  cyanobactins  have  not  been  described,  however,  strains  of  the  
genus Microcystis produce cyclic peptides called aeruginazoles, which are 
proposed to be cyanobactins (Table 2) (Raveh and Carmeli 2010, Adiv et al. 
2012). These cyanobactins are 12 to 17 amino acids with thiazoles and two of 
these contain chlorinated tyrosine (Adiv et al. 2012). Myriastramides are 
cyanobactin-like octapeptides detected from a sponge (Erickson et al. 2003). 
Myriastramide B contains a chlorinated O-prenyl moiety, which is attached 
to a tyrosine amino acid (Erickson et al. 2003). 
 
Just a few of the cyanobactins consist solely of proteinogenic amino acids 
without any modifications beyond N-to-C macrocyclization. In addition to 
post-translational modifications, the huge diversity of cyanobactins is 
derived directly from the genetic variation of cyanobactin precursor peptide 
genes. The core region of the precursor gene is not conserved making the 
amino acid content of cyanobactins hypervariable. Linear compounds 
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structurally related to cyanobactins have also been described (Carrol et al. 
1995, Nagatsu et al. 1995, Lawton et al. 1999, Table 3.). These linear 
tetrapeptides have methylated, decarboxylated, or prenylated C-terminus 
and the N-terminus is prenylated (Table 3 Carrol et al. 1995 Nagatsu et al. 
1995, Lawton et al. 1999). The biosynthetic pathway of these metabolites has 
not been described, but the production of virenamide and aeruginosamide 
has been suggested to be ribosomal in origin (Schmidt and Donia 2010). 
 


Figure 2. The chemical structure of selected cyclic cyanobactins. Patellamide, 
ulithiacyclamide, and trunkamide are produced by Prochloron (Schmidt et al. 2005, Donia 
et al. 2008a). Trichamide is produced by Trichodesmium erythraeum IMS101 (Sudek et al. 
2006) and microcyclamide by Microcystis aeruginosa NIES 298 (Ishida et al.  2000, Ziemert 
et al. 2008b). The post-translational modifications; oxazoline, thiazole, and reverse O-
prenyl are highlighted with circles. 

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 a
m
in
o 
ac
id
s 
Am
in
o 
ac
id
s o
f t
he
 
co
re
 p
ep
tid
e 
(N
-t
o-
C 
cy
cl
ic
) 
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
SS-bridge 
 B
io
ac
tiv
ity
 
So
ur
ce
 o
rg
an
is
m
 
Re
fe
re
nc
e 
 
A
sc
id
ia
cy
c
la
m
id
e
  
 
7
5
7
.0
 
8
 
IT
VC
IT
VC
 
 
2
 
2
 
 
 
 
C
y
to
to
x
ic
 
Li
ss
oc
lin
um
 p
at
el
la
  
Is
h
id
a
 e
t 
a
l.
 1
9
8
8
, 
S
c
h
m
it
z 
e
t 
a
l.
 1
9
8
9
 
A
x
in
a
st
a
ti
n
 1
 
A
x
in
a
st
a
ti
n
 2
 
A
x
in
a
st
a
ti
n
 3
 
7
5
2
.9
 
7
6
6
.9
 
7
8
1
.0
 
7
 
7
 
7
 
FV
VP
VN
P 
FV
LP
VN
P 
FI
LP
VN
P 
 
 
 
 
 
 
C
y
to
st
a
ti
c
 a
g
a
in
st
 
c
a
n
c
e
r 
c
e
ll
s 
Ax
in
el
la
 sp
. 
 
P
e
tt
it
 e
t 
a
l.
 1
9
9
4
 
  
A
x
in
e
ll
in
 C
 
9
3
8
.1
 
8
 
FP
LT
VP
WP
 
 
 
 
 
 
 
 
St
yl
ot
el
la
 a
ur
an
tiu
m
  
T
a
b
u
d
ra
v
u
 e
t 
a
l.
 2
0
0
2
a
 
B
is
tr
a
ta
m
id
e
 A
 
B
is
tr
a
ta
m
id
e
 B
 
B
is
tr
a
ta
m
id
e
 C
 
B
is
tr
a
ta
m
id
e
 D
 
B
is
tr
a
ta
m
id
e
 E
  
B
is
tr
a
ta
m
id
e
 F
 
B
is
tr
a
ta
m
id
e
 G
 
B
is
tr
a
ta
m
id
e
 H
 
B
is
tr
a
ta
m
id
e
 I
 
B
is
tr
a
ta
m
id
e
 J
 
5
7
0
.7
 
5
6
8
.7
 
5
0
3
.6
 
5
3
0
.6
 
5
4
3
.2
 
5
3
2
.7
 
5
2
8
.6
 
5
4
4
.7
 
5
4
8
.7
 
5
6
4
.7
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
6
 
IT
AC
FC
 
IT
AC
FC
 
VS
AC
VC
 
VT
VS
VC
 
VT
VC
VC
 
VT
VS
VC
 
VT
VS
VC
 
VT
VC
VC
 
VT
VS
VC
 
VT
VC
VC
 
  1
 
1
 
  2
 
1
 
1
 
1
 
1
 
 1
 
1
 
2
 
 1
 
2
 
1
 
2
 
1
 
1
 
2
 
1
 
2
 
2
 
1
 
  
 
 
C
y
to
to
x
ic
 
Li
ss
oc
lin
um
 b
ist
ra
tu
m
 
 
D
e
g
n
a
n
 e
t 
a
l.
 1
9
8
9
b
, 
 
F
o
st
e
r 
e
t 
a
l.
 1
9
9
2
, 
P
e
re
z 
a
n
d
 F
a
u
lk
n
e
r 
2
0
0
3
 
C
o
m
o
ra
m
id
e
 A
 
C
o
m
o
ra
m
id
e
 B
 
 
6
6
8
.9
 
6
8
6
.9
 
6
 
6
 
IT
FT
AC
 
IT
FT
AC
 
 
1
  
 
1
 
1
 
1
T
 
1
T
 
 
M
il
d
 c
y
to
to
x
ic
it
y
 
a
g
a
in
st
 t
u
m
o
u
r 
c
e
ll
s 
Di
de
m
nu
m
 m
ol
le
  
 
R
u
d
i 
e
t 
a
l.
 1
9
9
8
 
C
y
c
lo
d
id
e
m
n
a
m
id
e
 
C
y
c
lo
d
id
e
m
n
a
m
id
e
 B
 
6
9
3
.9
 
6
8
9
.9
 
7
 
7
 
FT
VP
CV
C 
IT
VP
CL
C 
 
1
 
1
 
2
 
1
  
 
 
W
e
a
k
ly
 c
y
to
to
xi
c 
Di
de
m
nu
m
 m
ol
le
  
T
o
sk
e
 a
n
d
 F
e
n
ic
a
l 
1
9
9
5
, 
A
rr
a
u
lt
 e
t 
a
l.
 2
0
0
2
 
C
y
c
lo
n
e
ll
in
 
9
6
3
.1
 
8
 
YT
AN
PR
YP
 
 
 
 
 
 
 
 
Ax
in
el
la
 ca
rt
er
i  
M
il
a
n
o
w
sk
i 
e
t 
a
l.
 2
0
0
4
 
C
y
c
lo
x
a
zo
li
n
e
 
5
4
6
.7
 
6
 
VT
VT
VT
 
 
3
 
 
 
 
 
C
y
to
to
x
ic
 
Li
ss
oc
lin
um
 b
ist
ra
tu
m
 
H
a
m
b
le
y
 e
t 
a
l.
 1
9
9
2
 
D
id
m
o
la
m
id
e
 A
 
D
id
m
o
la
m
id
e
 B
 
5
3
8
.6
 
5
5
6
.7
 
6
 
6
 
AC
FT
AC
 
AC
FT
AC
 
 
1
 
2
 
2
 
 
 
 
 
Di
de
m
nu
m
 m
ol
le
  
R
u
d
i 
e
t 
a
l.
 2
0
0
3
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N
um
be
r 
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m
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o 
ac
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s 
Am
in
o 
ac
id
s o
f t
he
 
co
re
 p
ep
tid
e 
(N
-t
o-
C 
cy
cl
ic
) 
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
SS-bridge 
 B
io
ac
tiv
ity
 
So
ur
ce
 o
rg
an
is
m
 
Re
fe
re
nc
e 
 
D
o
la
st
a
ti
n
 I
 
5
1
6
.6
 
6
 
IT
VS
AC
 
1
 
1
 
1
 
 
 
 
C
y
to
to
x
ic
 
Do
la
be
lla
 a
ur
icu
la
ria
 
(s
e
a
 h
a
re
) 
S
o
n
e
 e
t 
a
l.
 1
9
9
7
 
D
o
la
st
a
ti
n
 E
 
4
9
0
.6
 
6
 
AS
AC
IC
 
1
 
 
1
 
1
 
 
 
 
Do
la
be
lla
 a
ur
icu
la
ria
 
O
ji
k
a
 e
t 
a
l.
 1
9
9
5
 
H
a
li
cl
o
n
a
m
id
e
 A
 
H
a
li
cl
o
n
a
m
id
e
 B
 
H
a
li
cl
o
n
a
m
id
e
 D
 
H
a
li
cl
o
n
a
m
id
e
 E
 
8
5
7
.0
 
7
8
8
.9
 
8
0
6
.9
 
8
7
5
.0
 
8
 
8
 
8
 
8
 
PA
SY
PT
IP
 
PA
SY
PT
IP
 
PA
SY
PT
IP
 
PA
SY
PT
IP
 
1
 
1
 
1
 
1
 
1
 
1
 
 
 
1
Y
 
  
1
Y
 
 
A
n
ti
fo
u
li
n
g
 
 
Ha
lic
lo
na
 sp
.  
G
u
a
n
 e
t 
a
l.
 2
0
0
1
, 
S
e
ra
 e
t 
a
l.
 2
0
0
3
 
H
e
x
a
m
o
ll
a
m
id
e
 
6
9
6
.9
 
6
 
VV
CT
FP
 
 
 
 
1
 
1
T
 
 
M
o
d
e
ra
te
 
c
y
to
to
x
ic
it
y
 a
g
a
in
st
 
H
e
L
a
 S
3
 c
e
ll
s 
Di
de
m
nu
m
 
m
ol
le
  
T
e
ru
y
a
 e
t 
a
l.
 2
0
0
8
 
H
y
m
e
n
a
m
id
e
 A
 
H
y
m
e
n
a
m
id
e
 B
 
H
y
m
e
n
a
m
id
e
 C
 
H
y
m
e
n
a
m
id
e
 D
 
H
y
m
e
n
a
m
id
e
 E
 
H
y
m
e
n
a
m
id
e
 F
 
H
y
m
e
n
a
m
id
e
 G
 
H
y
m
e
n
a
m
id
e
 H
 
H
y
m
e
n
a
m
id
e
 J
 
H
y
m
e
n
a
m
id
e
 K
 
8
8
0
.1
 
8
3
0
.9
 
8
2
6
.9
 
7
6
9
.9
 
8
5
4
.0
 
7
6
5
.0
 
8
9
3
.1
 
9
0
4
.1
 
1
0
9
9
.3
 
1
0
0
7
.2
 
7
 
7
 
7
 
7
 
7
 
7
 
8
 
8
 
8
 
8
 
VP
FW
RP
P 
NF
VE
FP
P 
FG
PE
LW
P 
YD
PL
AI
P 
TT
PY
FF
P 
AV
ML
RP
P 
YV
PL
IL
PP
 
LP
WV
PL
TP
 
YD
FW
KV
YP
 
YD
FW
KA
VP
 
 
 
 
 
 
 
  Im
m
u
n
o
m
o
d
u
la
ti
n
g
 
a
c
ti
v
it
y
 
Hy
m
en
ia
cid
on
 sp
. 
(s
p
o
n
g
e
) 
K
o
b
a
y
a
sh
i 
e
t 
a
l.
 1
9
9
3
, 
 N
a
p
o
li
ta
n
o
 e
t 
a
l.
 2
0
0
1
, 
  K
o
b
a
y
a
sh
i 
e
t 
a
l.
 1
9
9
6
, 
T
su
d
a
 e
t 
a
l.
 1
9
9
4
 
K
e
e
n
a
m
id
e
 
6
2
1
.3
 
6
 
IP
GS
LC
 
 
 
 
1
 
1
S
 
 
A
c
ti
v
e
 a
g
a
in
st
 
tu
m
o
u
r 
c
e
ll
 l
in
e
s 
Pl
eu
ro
br
an
ch
us
 fo
rs
ka
lii
 
W
e
ss
o
n
 e
t 
a
l.
 1
9
9
6
 
L
e
u
c
a
m
id
e
 
6
1
1
.3
 
7
 
TA
SL
PV
C 
2
 
 
1
 
 
 
 
M
o
d
e
ra
te
ly
 c
y
to
to
x
ic
 
a
g
a
in
st
 t
u
m
o
u
r 
c
e
ll
 
li
n
e
s 
Le
uc
et
ta
 m
icr
or
ap
hi
s 
K
e
h
ra
u
s 
e
t 
a
l.
 2
0
0
2
 
L
is
so
c
li
n
a
m
id
e
 1
 
L
is
so
c
li
n
a
m
id
e
 2
 
L
is
so
c
li
n
a
m
id
e
 3
 
L
is
so
c
li
n
a
m
id
e
 4
 
L
is
so
c
li
n
a
m
id
e
 5
 
L
is
so
c
li
n
a
m
id
e
 6
 
L
is
so
c
li
n
a
m
id
e
 7
 
L
is
so
c
li
n
a
m
id
e
 8
 
7
0
5
.9
 
6
7
9
.9
 
6
7
9
.9
 
7
4
1
.9
 
7
3
9
.9
 
7
4
1
.9
 
7
4
3
.9
 
7
4
1
.9
 
7
 
7
 
7
 
7
 
7
 
7
 
7
 
7
 
IC
FP
TV
C 
AC
FP
TI
C 
AC
FP
TI
C 
FC
FP
TV
C 
FC
FP
TV
C 
FC
FP
TV
C 
FC
FP
TV
C 
FC
FP
TV
C 
 
1
 
1
 
1
 
1
 
1
 
1
 
1
 
1
 
2
 
1
 
1
 
1
 
2
 
1
 
 1
 
 1
 
1
 
1
 
 1
 
2
 
1
 
 
 
C
y
to
to
x
ic
 
 
Li
ss
oc
lin
um
 p
at
el
la
* 
 
W
a
sy
ly
k
 e
t 
a
l.
 1
9
8
3
, 
D
e
g
n
a
n
 e
t 
a
l.
 1
9
8
9
a
, 
 
S
c
h
m
it
z 
e
t 
a
l.
 1
9
8
9
, 
D
o
n
ia
 e
t 
a
l.
 2
0
0
6
, 
H
a
w
k
in
s 
e
t 
a
l.
 1
9
9
0
, 
M
o
rr
is
 e
t 
a
l.
 2
0
0
0
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N
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m
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s 
Am
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o 
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he
 
co
re
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ep
tid
e 
(N
-t
o-
C 
cy
cl
ic
) 
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
SS-bridge 
 B
io
ac
tiv
ity
 
So
ur
ce
 o
rg
an
is
m
 
Re
fe
re
nc
e 
 
L
is
so
c
li
n
a
m
id
e
 9
 
L
is
so
c
li
n
a
m
id
e
 1
0
 
7
0
7
.9
 
7
2
6
.9
 
7
 
7
 
VC
FP
TI
C 
IC
FP
TI
C 
 
1
 
1
 
1
 
1
 
2
 
 
 
 
 
 
M
a
y
o
ta
m
id
e
 A
 
M
a
y
o
ta
m
id
e
 B
 
6
9
4
.0
 
6
7
9
.9
 
7
 
7
 
VP
CI
CM
C 
VP
CV
CM
C 
 
 
1
 
1
 
2
 
2
 
 
 
 
Di
de
m
nu
m
 m
ol
le
 
 
R
u
d
i 
e
t 
a
l.
 1
9
9
8
 
M
in
im
id
e
 
7
2
1
.4
 
6
 
TL
AT
IC
 
 
 
 
1
 
2
S
 
 
 
Di
de
m
nu
m
 m
ol
le
 
D
o
n
ia
t 
e
t 
a
l.
 2
0
1
1
 
M
o
ll
a
m
id
e
 
8
0
8
.0
 
7
 
IP
IS
FP
C 
 
 
 
1
 
1
S
 
 
C
y
to
to
x
ic
 
Di
de
m
nu
m
 m
ol
le
 
D
o
n
ia
 e
t 
a
l.
 2
0
0
8
b
 
M
o
ll
a
m
id
e
 B
 
M
o
ll
a
m
id
e
 C
 
6
9
6
.9
 
6
1
8
.8
 
6
 
6
 
VF
PT
VC
 
IP
GS
LC
 
 
 
 1
 
1
 
1
T
 
1
S
 
 
C
y
to
to
x
ic
 a
g
a
in
st
 
se
v
e
ra
l 
c
a
n
c
e
r 
c
e
ll
 
li
n
e
s 
 
 
M
y
ri
a
st
ra
m
id
e
 A
 
M
y
ri
a
st
ra
m
id
e
 B
 
M
y
ri
a
st
ra
m
id
e
 C
 
8
5
4
.3
 
8
8
8
.4
 
8
2
7
.4
 
8
 
8
 
8
 
IT
YP
SA
PP
 
IT
YP
SA
PP
 
VS
VW
CV
PP
 
2
 
2
 
1
 
 
  1
 
 
Y
 
Y
†
 
 
 
  
M
yr
ia
st
ra
 c
la
vo
sa
  
(s
p
o
n
g
e
) 
E
ri
c
k
so
n
 e
t 
a
l.
 2
0
0
3
 
N
a
ir
a
ia
m
id
e
 A
 
N
a
ir
a
ia
m
id
e
 B
 
8
0
2
.1
 
8
1
6
.1
 
7
 
7
 
VT
IP
II
P 
IT
IP
II
P 
 
 
 
 
1
T
 
1
T
 
 
 
Li
ss
oc
lin
um
 b
ist
ra
tu
m
  
F
o
st
e
r 
a
n
d
 I
re
la
n
d
 1
9
9
3
 
P
a
te
ll
a
m
id
e
 A
 
P
a
te
ll
a
m
id
e
 B
 
P
a
te
ll
a
m
id
e
 C
 
P
a
te
ll
a
m
id
e
 D
 
P
a
te
ll
a
m
id
e
 E
 
P
a
te
ll
a
m
id
e
 F
 
P
a
te
ll
a
m
id
e
 G
 
 
7
4
3
.0
 
7
7
7
.0
 
7
6
3
.0
 
7
7
7
.0
 
7
9
1
.0
 
7
6
3
.0
 
7
9
5
.0
 
8
 
8
 
8
 
8
 
8
 
8
 
8
  
IS
VC
IT
VC
 
LT
AC
IT
FC
 
VT
AC
IT
FC
 
IT
AC
IT
FC
 
VT
VC
IT
FC
 
VT
VC
IT
FC
 
IT
AC
LT
FC
 
 
2
 
2
 
2
 
2
 
2
 
2
 
1
 
2
 
2
 
2
 
2
 
2
 
2
 
2
 
 
 
 
C
y
to
to
x
ic
 
a
n
ti
n
e
o
p
la
st
ic
, 
P
a
te
ll
a
m
id
e
s 
B
 a
n
d
 C
 
h
a
d
 m
u
lt
id
ru
g
 
re
v
e
rs
in
g
 a
c
ti
v
it
y
  
Li
ss
oc
lin
um
 p
at
el
la
* 
 
Ir
e
la
n
d
 e
t 
a
l.
 1
9
8
2
, 
 
F
u
 e
t 
a
l.
 1
9
9
8
, 
S
c
h
m
it
z 
e
t 
a
l.
 1
9
8
9
, 
M
c
D
o
n
a
ld
 a
n
d
 I
re
la
n
d
 
1
9
9
2
, 
 
R
a
sh
id
 e
t 
a
l.
 1
9
9
5
, 
 
S
c
h
m
id
t 
e
t 
a
l 
2
0
0
5
, 
D
o
n
ia
 e
t 
a
l.
 2
0
0
6
 
P
a
te
ll
in
 2
 
P
a
te
ll
in
 3
 
P
a
te
ll
in
 6
 
7
3
3
.0
 
9
4
3
.0
 
9
6
3
.2
 
6
 
8
 
8
 
TV
PT
LC
 
TL
PV
PT
LC
 
TF
PV
PT
VC
 
 
 
 
1
 
1
 
1
 
2
T
 
2
T
 
2
T
 
 
 M
o
d
e
ra
te
ly
 c
y
to
to
x
ic
  
 
Li
ss
oc
lin
um
 p
at
el
la
* 
D
o
n
ia
 e
t 
a
l.
 2
0
0
8
a
, 
 
Z
a
b
ri
sk
ie
 e
t 
a
l.
 1
9
9
0
 
P
h
a
k
e
ll
is
ta
ti
n
 1
 
  P
h
a
k
e
ll
is
ta
ti
n
 2
 
8
2
8
.0
 
  8
2
8
.0
 
7
   7
 
YP
IP
IF
P 
  YP
FP
II
P 
 
 
 
 
 
 
C
a
n
c
e
r 
c
e
ll
 g
ro
w
th
 
in
h
ib
it
o
ry
 
C
e
ll
 g
ro
w
th
 
in
h
ib
it
o
ry
 
Ph
ak
el
lia
 co
st
at
a 
(s
p
o
n
g
e
) a
n
d
 S
ty
lo
te
lla
 
au
ra
nt
iu
m
 
Ph
ak
el
lia
 ca
rt
er
i 
P
e
tt
it
 e
t 
a
l.
 1
9
9
3
a
, 
b
, 
  T
a
b
u
d
ra
v
u
 e
t 
a
l.
 2
0
0
2
b
 
P
h
a
k
e
ll
is
ta
ti
n
 7
 
P
h
a
k
e
ll
is
ta
ti
n
 8
 
P
h
a
k
e
ll
is
ta
ti
n
 9
 
1
1
0
9
.4
 
1
1
3
7
.4
 
1
1
2
3
.4
 
1
0
 
1
0
 
1
0
 
YI
PP
IF
AL
PP
 
YI
PP
IF
VL
PP
 
YV
PP
IF
VL
PP
 
 
 
 
 
 
 
C
a
n
c
e
r 
c
e
ll
 g
ro
w
th
 
in
h
ib
it
o
ry
 
Ph
ak
el
lia
 co
st
at
a 
sp
o
n
g
e
 
P
e
tt
it
 e
t 
a
l.
 1
9
9
5
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m
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s 
Am
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o 
ac
id
s o
f t
he
 
co
re
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ep
tid
e 
(N
-t
o-
C 
cy
cl
ic
) 
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
SS-bridge 
 B
io
ac
tiv
ity
 
So
ur
ce
 o
rg
an
is
m
 
Re
fe
re
nc
e 
 
P
h
a
k
e
ll
is
ta
ti
n
 1
2
 
P
h
a
k
e
ll
is
ta
ti
n
 1
3
 
1
1
3
9
.4
 
7
9
8
.9
 
1
0
 
7
 
IF
TL
PP
YI
PP
 
TL
WP
FG
P 
 
 
 
 
 
 
 
Ph
ak
el
lia
 sp
. 
Ph
ak
el
lia
 fu
sc
a 
(s
p
o
n
g
e
) 
P
e
tt
it
 a
n
d
 T
a
n
 2
0
0
3
, 
L
i 
e
t 
a
l.
 2
0
0
3
 
S
ty
li
si
n
 1
 
S
ty
li
si
n
 2
 
8
2
8
.0
 
8
1
2
.0
 
7
 
7
 
LP
YP
IF
P 
IP
YP
PF
P 
 
 
 
 
 
 
 
St
yl
iss
a 
ca
rib
ica
 
(s
p
o
n
g
e
) 
M
o
h
a
m
m
e
d
 e
t 
a
l.
 2
0
0
6
 
S
ty
li
ss
a
m
id
e
 A
 
S
ty
li
ss
a
m
id
e
 B
 
S
ty
li
ss
a
m
id
e
 C
 
S
ty
li
ss
a
m
id
e
 D
 
8
4
5
.0
 
8
1
2
.0
 
8
6
2
.0
 
8
2
8
.0
 
7
 
7
 
7
 
7
 
VY
PY
KP
P 
IY
PF
PP
P 
FI
PY
PF
P 
FI
PY
PL
P 
 
 
 
 
 
 
 
St
yl
iss
a 
ca
rib
ica
 
(s
p
o
n
g
e
) 
S
c
h
m
id
t 
e
t 
a
l.
 2
0
0
7
 
T
a
w
ic
y
cl
a
m
id
e
 A
 
T
a
w
ic
y
cl
a
m
id
e
 B
 
8
0
6
.1
 
7
7
2
.0
 
8
 
8
 
VC
FC
IC
VP
 
VC
LC
IC
VP
 
 
 
2
 
2
 
1
 
1
 
 
 
W
e
a
k
ly
 c
y
to
to
xi
c 
Li
ss
oc
lin
um
 p
at
el
la
 
M
c
D
o
n
a
ld
 e
t 
a
l.
 1
9
9
2
 
T
ru
n
k
a
m
id
e
 A
 
8
3
8
.0
 
7
 
TS
IA
PF
C 
 
 
 
1
 
2
T
S
 
 
C
y
to
to
x
ic
, 
m
u
lt
id
ru
g
 
re
v
e
rs
in
g
 a
c
ti
v
it
y
  
Li
ss
oc
lin
um
 p
at
el
la
* 
C
a
b
a
 e
t 
a
l.
 2
0
0
1
, 
 
S
a
lv
a
te
ll
a
 e
t 
a
l.
 2
0
0
3
, 
 
D
o
n
ia
 e
t 
a
l.
 2
0
0
8
a
  
U
li
c
y
c
la
m
id
e
 
6
7
7
.8
 
7
 
FP
TI
CA
C 
 
1
 
2
 
 
 
 
N
o
t 
re
p
o
rt
e
d
 
Li
ss
oc
lin
um
 p
at
el
la
 
Ir
e
la
n
d
 a
n
d
 S
c
h
e
u
e
r 
1
9
8
0
, 
W
a
sy
ly
k
 e
t 
a
l.
 1
9
8
3
 
U
li
th
ia
c
y
c
la
m
id
e
 
U
li
th
ia
c
y
c
la
m
id
e
 B
 
U
li
th
ia
c
y
c
la
m
id
e
 E
 
U
li
th
ia
c
y
c
la
m
id
e
 F
 
U
li
th
ia
c
y
c
la
m
id
e
 G
 
7
6
3
.0
 
7
9
7
.0
 
8
3
3
.0
 
8
1
5
.0
 
8
1
5
.0
 
8
 
8
 
8
 
8
 
8
 
CT
LC
CT
LC
 
CT
FC
CT
LC
 
CT
FC
CT
LC
 
CT
FC
CT
LC
 
CT
FC
CT
LC
 
 
2
 
2
  1
 
1
 
2
 
2
 
2
 
2
 
2
 
 
 
1
 
1
 
1
 
1
 
1
 
C
y
to
to
x
ic
 
 
Li
ss
oc
lin
um
 p
at
el
la
* 
 
Ir
e
la
n
d
 a
n
d
 S
c
h
e
u
e
r 
1
9
8
0
, 
Ir
e
la
n
d
 e
t 
a
l.
 1
9
8
2
, 
W
il
li
a
m
s 
e
t 
a
l.
 1
9
8
9
, 
F
u
 e
t 
a
l.
 1
9
9
8
 
W
a
in
u
n
u
a
m
id
e
 
7
4
5
.9
 
7
 
GL
FP
HP
P 
 
 
 
 
 
 
W
e
a
k
ly
 c
y
to
to
x
ic
 
St
yl
ot
el
la
 a
ur
an
tiu
m
 
(s
p
o
n
g
e
) 
T
a
b
u
d
ra
v
u
 e
t 
a
l.
 2
0
0
1
 
W
a
ia
k
e
a
m
id
e
 
8
1
2
.2
 
6
 
FP
MP
PM
C 
 
 
 
1
 
 
 
A
n
ti
fo
u
li
n
g
 
Ha
lic
lo
na
 (s
p
o
n
g
e
) 
M
a
u
 e
t 
a
l.
 1
9
9
6
, 
 
S
e
ra
 e
t 
a
l.
 2
0
0
3
 
*
C
o
m
p
o
u
n
d
s 
a
re
 c
o
n
fi
rm
e
d
 t
o
 b
e
 p
ro
d
u
c
e
d
 b
y
 t
h
e
 P
ro
ch
lo
ro
n 
sp
p
. 
sy
m
b
io
ti
c
 p
a
rt
n
e
rs
 o
f 
a
sc
id
ia
n
 (
in
d
ic
a
te
d
 w
it
h
 a
n
 a
st
e
ri
sk
 a
ft
e
r 
th
e
 s
o
u
rc
e
 o
rg
a
n
is
m
) 
a
n
d
 t
h
e
 
b
io
sy
n
th
e
ti
c
 g
e
n
e
s 
h
a
v
e
 b
e
e
n
 d
e
sc
ri
b
e
d
. 
†
C
h
lo
ri
n
a
te
d
 p
re
n
y
l 
 
†
†
 T
h
is
 t
a
b
le
 h
a
s 
b
e
e
n
 m
o
d
if
ie
d
 f
ro
m
 t
h
e
 o
ri
g
in
a
l 
ta
b
le
 p
re
se
n
te
d
 i
n
 S
iv
o
n
e
n
 e
t 
a
l.
 2
0
1
0
. 
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Ta
bl
e 
2.
 T
he
 s
tr
uc
tu
ra
l f
ea
tu
re
s 
of
 c
ya
no
ba
ct
in
s 
an
d 
pu
ta
tiv
e 
cy
an
ob
ac
tin
s.
 T
h
e
 p
e
p
ti
d
e
s 
a
re
 o
rg
a
n
iz
e
d
 a
c
c
o
rd
in
g
 t
o
 t
h
e
 a
lp
h
a
b
e
ti
c
a
l 
o
rd
e
r 
o
f 
th
e
 c
o
m
p
o
u
n
d
 
n
a
m
e
. 
T
h
e
 s
e
q
u
e
n
c
e
 o
f 
th
e
 p
e
p
ti
d
e
 i
s 
p
re
se
n
te
d
 i
n
 l
in
e
a
r 
fo
rm
 s
o
 t
h
a
t 
th
e
 l
a
st
 a
m
in
o
 a
c
id
 i
s 
c
y
st
e
in
e
, 
p
ro
li
n
e
 o
r 
th
re
o
n
in
e
. 
N
u
m
b
e
r 
o
f 
h
e
te
ro
c
y
c
li
ze
d
 a
m
in
o
 
a
c
id
s 
is
 g
iv
e
n
 a
ft
e
r 
th
e
 c
o
re
 p
e
p
ti
d
e
. 
T
h
is
 t
a
b
le
 i
n
c
lu
d
e
s 
a
ls
o
 t
h
e
 c
y
a
n
o
b
a
c
ti
n
s 
d
e
sc
ri
b
e
d
 i
n
 t
h
e
 p
u
b
li
c
a
ti
o
n
s 
II
 a
n
d
 I
II
. 
 
Co
m
po
un
d 
Molecular  
weight 
Number (aa) 
Am
in
o 
ac
id
s o
f t
he
 c
or
e 
pe
pt
id
e 
(N
-t
o-
C 
cy
cl
ic
) 
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
Geranyl 
S-S bridge 
 B
io
ac
tiv
ity
 
Pr
od
uc
er
 
Re
fe
re
nc
es
 
A
e
ru
c
y
c
la
m
id
e
 A
 
A
e
ru
c
y
c
la
m
id
e
 B
 
A
e
ru
c
y
c
la
m
id
e
 C
 
A
e
ru
c
y
c
la
m
id
e
 D
 
(f
o
rm
e
rl
y
 
m
ic
ro
c
y
c
la
m
id
e
 7
8
0
6
A
 
a
n
d
 B
)*
 
5
3
4
.7
 
5
3
2
.7
 
5
1
6
.6
 
5
8
6
.7
 
6
 
6
 
6
 
6
 
IT
GC
IC
 
IT
GC
IC
 
AT
VS
IC
 
FT
GC
MC
 
 
  1
 
1
 
1
 
1
 
1
 
1
 
2
 
1
 
1
 
1
   1
 
 
 
 
T
o
x
ic
 t
o
 f
re
sh
 w
a
te
r 
c
ru
st
a
c
e
a
n
 
T
h
a
m
n
o
c
e
p
h
a
lu
s 
p
la
ty
u
ru
s,
 
a
n
ti
m
a
la
ri
a
l 
M
icr
oc
ys
tis
 a
er
ug
in
os
a 
(b
lo
o
m
-f
o
rm
in
g
, 
p
la
n
k
to
n
ic
) 
Z
ie
m
e
rt
 e
t 
a
l.
 2
0
0
8
b
, 
R
e
v
is
e
d
 s
tr
u
c
tu
re
s 
a
n
d
 
re
n
a
m
in
g
: 
P
o
rt
m
a
n
n
 e
t 
a
l.
 2
0
0
8
a
, 
b
 
A
e
st
u
a
ra
m
id
e
 1
–
6
*
 
A
e
st
u
a
ra
m
id
e
 7
–
1
2
*
 
7
9
4
.0
  
8
2
2
.0
 
7
 
7
 
VC
MP
CY
P 
 
AC
MP
CY
P 
 
 
2
 
2
 
 
1
Y
 
1
Y
 
 
 
 
Ly
ng
by
a 
ae
st
ua
rii
 
 P
C
C
 8
1
0
6
 
D
o
n
ia
 e
t 
a
l.
 2
0
0
8
, 
 
M
c
In
to
sh
 e
t 
a
l.
 2
0
1
3
 
A
e
ru
g
in
a
zo
le
 A
 
1
1
5
5
.4
 
1
2
 
GG
GV
FV
CL
CY
NC
 
 
 
3
 
 
 
 
 
A
n
ti
m
ic
ro
b
ia
l 
M
icr
oc
ys
tis
 s
p
. 
st
ra
in
 I
L
-
3
2
3
 
R
a
v
e
h
 a
n
d
 C
a
rm
e
li
 2
0
1
0
 
A
e
ru
g
in
a
zo
le
 D
A
1
4
9
7
 
A
e
ru
g
in
a
zo
le
 D
A
1
3
0
4
 
A
e
ru
g
in
a
zo
le
 D
A
1
2
7
4
 
A
e
ru
g
in
a
zo
le
 D
A
1
3
3
8
 
A
e
ru
g
in
a
zo
le
 D
A
1
3
7
2
 
1
4
9
7
.5
 
1
3
0
4
.4
 
1
2
7
4
.4
 
1
3
3
8
.4
 
1
3
7
2
.4
 
1
7
 
1
3
 
1
3
 
1
3
 
1
3
 
IA
GF
CG
PL
CV
GP
VC
SA
C 
GG
SG
FF
IC
LC
YN
C 
GG
GG
FF
IC
LC
YN
C 
GG
SG
FF
IC
LC
YN
C †
 
GG
SG
FF
IC
LC
YN
C †
 
 
 
4
 
3
 
3
 
3
 
3
 
 
 
 
 
A
n
ti
m
ic
ro
b
ia
l 
(D
A
1
4
9
7
) 
  
M
icr
oc
ys
ti s
 b
lo
o
m
 
A
d
iv
 e
t 
a
l.
 2
0
1
2
 
A
g
a
rd
h
ip
e
p
ti
n
 
A
 
A
g
a
rd
h
ip
e
p
ti
n
 B
 
8
3
4
.0
 
1
0
3
6
.3
 
7
 
8
 
WG
LH
GW
P 
WA
PW
VW
LP
 
 
 
 
 
 
 
 
P
la
sm
in
 i
n
h
ib
it
o
ry
 
Os
cil
la
to
ria
 a
ga
rd
hi
i  
N
IE
S
2
0
4
 (
fr
e
sh
w
a
te
r)
 
S
h
in
 e
t 
a
l.
 1
9
9
6
 
A
n
a
c
y
c
la
m
id
e
 A
1
0
*
 
1
0
5
3
.2
 
1
0
 
TS
QI
WG
SP
VP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 e
.g
. 
9
0
 
A
rt
ic
le
 I
I 
A
n
a
c
y
c
la
m
id
e
 B
1
0
*
 
1
0
1
0
.2
 
1
0
 
SS
VI
WG
SP
VP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 e
.g
. 
1
T
U
3
1
S
9
 
 
A
n
a
c
y
c
la
m
id
e
 C
1
0
*
 
1
1
1
5
.2
 
1
0
 
SA
QW
QN
FG
VP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 e
. 
g
. 
2
9
9
A
 
A
n
a
c
y
c
la
m
id
e
 D
1
0
*
 
1
1
5
1
.3
 
1
0
 
NA
HW
QN
FG
VP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 1
T
U
4
4
S
9
 
A
n
a
c
y
c
la
m
id
e
 E
1
0
*
 
1
0
8
7
.3
 
1
0
 
YA
PL
QN
FG
VP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 P
H
2
5
6
 
A
n
a
c
y
c
la
m
id
e
 E
1
0
P
*
 
1
1
5
5
.4
 
1
0
 
YA
PL
QN
FG
VP
 
 
 
 
 
1
 
 
 
 
An
ab
ae
na
 P
H
2
5
6
 
A
n
a
c
y
c
la
m
id
e
 A
1
1
*
 
1
2
8
1
.4
 
1
1
 
DN
WL
GE
WI
GI
P 
 
 
 
 
 
 
 
 
An
ab
ae
na
 e
.g
. B
IR
26
0 
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Co
m
po
un
d 
Molecular  
weight 
Number (aa) 
Am
in
o 
ac
id
s o
f t
he
 c
or
e 
pe
pt
id
e 
(N
-t
o-
C 
cy
cl
ic
) 
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
Geranyl 
S-S bridge 
 B
io
ac
tiv
ity
 
Pr
od
uc
er
 
Re
fe
re
nc
es
 
A
n
a
c
y
c
la
m
id
e
 A
1
5
*
 
1
6
9
0
.9
 
1
5
 
HA
FI
GY
DQ
DP
TG
KY
P 
 
 
 
 
 
 
 
 
An
ab
ae
na
 3
7
 
A
n
a
c
y
c
la
m
id
e
 A
1
5
G
*
 
1
8
2
7
.1
 
1
5
 
HA
FI
GY
DQ
DP
TG
KY
P 
 
 
 
 
1
 
 
 
 
An
ab
ae
na
 3
7
  
A
n
a
c
y
c
la
m
id
e
 A
7
*
 
9
4
8
.1
 
7
 
RE
RF
VY
P 
 
 
 
 
 
 
 
 
An
ab
ae
na
 1
T
U
3
9
S
8
 
A
n
a
c
y
c
la
m
id
e
 F
1
0
P
*
 
1
1
9
1
.3
 
1
0
 
YS
NK
PS
DF
SP
 
 
 
 
 
1
 
 
 
 
An
ab
ae
na
 1
T
U
3
2
S
1
1
 
A
n
a
c
y
c
la
m
id
e
 A
9
P
*
 
1
1
1
4
.3
 
9
 
YD
DK
LN
LS
P 
 
 
 
 
1
 
 
 
 
An
ab
ae
na
 1
T
U
3
3
S
1
0
 
A
n
a
c
y
c
la
m
id
e
 A
2
0
P
*
 
2
0
8
0
.4
 
2
0
 
WG
NG
TG
LD
WK
LL
TG
GI
SA
SP
 
 
 
 
 
1
 
 
 
 
An
ab
ae
na
 2
0
2
A
1
 
A
n
a
c
y
c
la
m
id
e
 A
2
0
P
P
*
 
2
1
4
8
.5
 
2
0
 
WG
NG
TG
LD
WK
LL
TG
GI
SA
SP
 
 
 
 
 
2
 
 
 
 
An
ab
ae
na
 2
0
2
A
1
 
A
n
a
c
y
c
la
m
id
e
 A
8
P
*
 
9
9
3
.1
 
8
 
HQ
PW
HA
AP
 
 
 
 
 
1
 
 
 
 
An
ab
ae
na
 T
R
2
3
2
 
A
n
a
c
y
c
la
m
id
e
 B
8
*
 
9
5
7
.1
 
8
 
FS
PD
WR
AP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 S
Y
K
E
8
1
6
 
A
n
a
c
y
c
la
m
id
e
 C
8
*
 
9
9
8
.2
 
8
 
VI
QH
YL
FP
 
 
 
 
 
 
 
 
 
An
ab
ae
na
 P
H
2
6
2
 
A
n
a
c
y
c
la
m
id
e
 B
7
*
 
7
6
2
.0
 
7
 
LI
GI
MH
P 
 
 
 
 
 
 
 
 
An
ab
ae
na
 S
Y
K
E
8
4
4
B
 
A
rt
h
ro
sp
ir
a
m
id
e
 A
*
 
A
rt
h
ro
sp
ir
a
m
id
e
 B
*
 
8
6
6
.3
 
9
2
4
.4
 
8
 
8
 
GL
PG
MP
CF
C 
GV
LG
MP
CF
C 
 
 
2
 
2
 
 
 
 
 
 
Ar
th
ro
sp
ira
 p
la
te
ns
is 
 N
IE
S
 3
9
 (
S
a
li
n
e
 l
a
k
e
) 
D
o
n
ia
 a
n
d
 S
c
h
m
id
t 
2
0
1
1
 
B
a
n
y
a
sc
y
cl
a
m
id
e
 A
 
B
a
n
y
a
sc
y
cl
a
m
id
e
 B
 
B
a
n
y
a
sc
y
cl
a
m
id
e
 C
 
5
3
8
.6
 
5
2
2
.7
 
5
5
6
.7
 
6
 
6
 
6
 
AC
FT
AC
 
AC
LT
AC
 
AC
FT
AC
 
 
1
 
2
 
2
 
2
 
 
 
 
 
 
N
os
to
c s
p
. 
T
A
U
 s
tr
a
in
 I
L
-
2
3
5
 (
b
lo
o
m
-f
o
rm
in
g
, 
p
la
n
k
to
n
ic
) 
P
lo
u
tn
o
 a
n
d
 C
a
rm
e
li
 2
0
0
2
 
C
y
a
n
o
th
e
c
a
m
id
e
 A
*
 
C
y
a
n
o
th
e
c
a
m
id
e
 B
*
 
C
y
a
n
o
th
e
c
a
m
id
e
 C
*
 
8
3
0
.4
 
8
2
8
.4
 
7
2
9
.3
 
7
 
7
 
7
 
VL
YK
DQ
C 
VL
YK
DQ
C 
KL
GD
SY
C 
 
  1
 
 1
 
1
  1
 
 
 
 
 
Cy
an
ot
he
ce
 P
C
C
 7
4
2
5
 
H
o
u
ss
e
n
 e
t 
a
l.
 2
0
1
2
 
D
e
n
d
ro
a
m
id
e
 A
 
D
e
n
d
ro
a
m
id
e
 B
 
D
e
n
d
ro
a
m
id
e
 C
  
4
8
8
.6
 
5
2
0
.6
 
5
3
6
.6
 
6
 
6
 
6
 
AC
AT
VC
 
AT
AC
MC
 
AT
AC
MC
 
1
 
1
 
1
 
 
2
 
2
 
2
 
 
 
 
 
A
 -
 M
u
lt
id
ru
g
-
re
si
st
a
n
c
e
 r
e
v
e
rs
in
g
 
a
c
ti
v
it
y
  
St
ig
on
em
a 
de
nd
ro
id
eu
m
 
(t
e
rr
e
st
ri
a
l)
 
O
g
in
o
 e
t 
a
l.
 1
9
9
6
 
D
o
la
st
a
ti
n
 3
 
H
o
m
o
d
o
la
st
a
ti
n
 3
 
6
6
0
.8
 
6
7
4
.8
 
7
 
7
 
VP
LQ
CG
C 
IP
LQ
CG
C 
2
 
2
 
 
Ly
ng
by
a 
m
aj
us
cu
la
 
M
it
c
h
e
ll
 e
t 
a
l.
 2
0
0
0
 
K
a
w
a
g
u
c
h
ip
e
p
ti
n
 A
 
1
4
2
1
 
1
1
 
WL
NG
DN
NW
ST
P 
 
 
 
 
2 W
 
 
 
 
M
icr
oc
ys
tis
 a
er
ug
in
os
a 
N
IE
S
 8
8
 (
fr
e
sh
w
a
te
r)
 
Is
h
id
a
 e
t 
a
l.
 1
9
9
6
 
K
a
w
a
g
u
c
h
ip
e
p
ti
n
 B
 
1
2
8
5
 
1
1
 
WL
NG
DN
NW
ST
P 
 
 
 
 
 
 
 
A
n
ti
b
a
c
te
ri
a
l 
M
icr
oc
ys
tis
 a
er
ug
in
os
a 
N
IE
S
 8
8
 
Is
h
id
a
 e
t 
a
l.
 1
9
9
7
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Co
m
po
un
d 
Molecular  
weight 
Number(aa) 
Am
in
o 
ac
id
s o
f t
he
 c
or
e 
pe
pt
id
e 
(N
-t
o-
C 
cy
cl
ic
)  
Oxazole 
Oxazoline 
Thiazole 
Thiazoline 
Prenyl 
Geranyl 
S-S bridge 
 B
io
ac
tiv
ity
 
Pr
od
uc
er
 
Re
fe
re
nc
es
 
K
o
ro
ra
m
id
e
 
9
6
9
.2
 
7
 
LY
CN
PS
LC
 
 
 
1
 
1
 
 
 
 
 
Ly
ng
by
a 
m
aj
us
cu
la
 
(M
a
ri
n
e
 l
a
k
e
) 
M
it
c
h
e
ll
 e
t 
a
l.
 2
0
0
0
 
M
ic
ro
c
y
c
la
m
id
e
*
 
5
8
2
.7
 
 
6
 
HC
AT
IC
 
 
1
 
 
2
 
 
 
 
 
M
o
d
e
ra
te
 
c
y
to
to
x
ic
it
y
 a
g
a
in
st
 
P
3
8
8
 m
u
ri
n
e
 
le
u
k
a
e
m
ia
 c
e
ll
s 
(I
C
5
0
 -
 1
.2
 μ
g
/m
l 
M
icr
oc
ys
ti s
 a
er
ug
in
os
a 
N
IE
S
 2
9
8
 (
fr
e
sh
w
a
te
r)
 
Is
h
id
a
 e
t 
a
l.
 2
0
0
0
, 
 
Z
ie
m
e
rt
 e
t 
a
l.
 2
0
0
8
b
 
M
ic
ro
p
h
y
c
in
 A
L8
2
8
 
8
2
9
 
8
 
EI
GV
YG
LP
 
 
 
 
 
 
 
 
 
M
icr
oc
ys
tis
 s
p
. 
T
A
U
 s
tr
a
in
 
IL
-3
0
6
 
G
e
sn
e
r-
A
p
te
r 
a
n
d
 C
a
rm
e
li
 
2
0
0
8
 
N
o
st
o
c
y
c
la
m
id
e
 
 
4
7
4
.6
 
6
 
AT
GC
VC
 
1
 
 
2
 
 
 
 
 
A
n
ti
c
y
a
n
o
b
a
c
te
ri
a
l 
a
n
d
 a
n
ti
a
lg
a
l,
 t
o
xi
c
 
a
ls
o
 t
o
 t
h
e
 r
o
ti
fe
r 
B
ra
c
c
h
io
n
u
s 
c
a
ly
ci
fl
o
ru
s 
 
N
os
to
c s
p
. 
3
1
 
T
o
d
o
ro
v
a
 e
t 
a
l.
 1
9
9
5
 
N
o
st
o
c
y
c
la
m
id
e
 M
 
5
0
6
.6
 
6
 
AT
GC
MC
 
1
 
 
2
 
 
 
 
 
A
ll
e
lo
p
a
th
ic
 
a
n
ti
c
y
a
n
o
b
a
c
te
ri
a
l 
 N
os
to
c s
p
. 
3
1
 
Jü
tt
n
e
r 
e
t 
a
l.
 2
0
0
1
 
O
sc
il
la
c
y
c
li
n
 
9
9
5
 
9
 
FT
TS
IA
YN
P 
 
 
 
 
 
 
 
 
Os
cil
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1.5.1. Bioactivities 
 
The  cyclic  peptide  structure  is  promising  in  drug  development  (Wipf  1995,  
Driggers et al. 2008). The macrocyclic structures have good properties for 
drug candidates such as good solubility, lipophility, stability, and 
bioavailability (Driggers et al. 2008). Cyclic peptides lack ionized C- and N-
termini, which makes the passage of such peptides across membranes easier, 
whilst increasing the resistance of the structure to enzyme degradation in 
vivo,  as  well  as  improving  the  bioavailability  of  the  peptide  (Wipf  1995).  
Other properties, which affect the bioactivity of the peptide, include the 
presence  of  heterocyclized  amino  acids  and  their  level  of  oxidation.  Minor  
changes  in  the  oxidation  level  of  heterocycles  can  change  the  bioactivity  
dramatically (Houssen and Jaspars 2010). Many cyanobactins have been 
discovered in the screening of potential bioactive compounds in different 
types of assays against various cancer cell lines (Table 1–3). As a 
consequence, most of the cyanobactins from marine animals have been 
shown to be cytotoxic (Donia and Schmidt 2010, Tables 1–3) in contrast to 
many other ribosomally-synthesised, modified peptides with antibacterial 
activities (Arnison et al. 2013). Studies on ulithiacyclamide, which has 
promising anticancer properties, were halted because of their high toxicity in 
animal models (Houssen and Jaspars 2010). Cyanobactins also have other 
interesting bioactivities, such as multi-drug resistance reversing properties, 
anti-malarial, anti-viral, and allelopathic activities (Tables 1–3). In many 
cases  there  is  no  bioactivity  reported.  The  evaluation  of  the  bioactivity  of  
cyanobactins is heavily dependent on the amount of the compound produced 
by the cyanobacterium. Many novel compounds await the development of a 
synthetic route for bioactivity investigations to commence (Wipf 1995). New 
developments in combinatorial biosynthesis and heterologous expression 
systems for cyanobactins may enable more bioactivity studies when the 
production levels become sufficient. 
 
1.5.2. Ecological role of cyanobactins 
 
The ecological role of cyanobactins is not understood. In contrast to 
traditional ribosomal peptides such as bacteriocins, which usually have 
antibacterial activities (Arnison et al. 2013), the cyanobactins have often 
been found in biomedical screenings (Tables 1-3). Cyanobactins have many 
described bioactivities, but allelopathy against competing cyanobacteria and 
antibacterial activities are described for only a few cyanobactins (Todorova et 
al. 1995, Ishida et al. 1997, Jüttner et al. 2001, Raveh and Carmeli 2010, Adiv 
et al. 2012). These activities may yield information about the ecological 
function of cyanobactins, unlike the bioactivities found by biomedical 
screening. The cyanobactins found from immobile marine animals have been 
shown to have antifouling properties to protect from fouling organisms (Sera 
et al. 2002 and 2003). The metal binding properties of Lissoclinum patella 
metabolites have been studied and molecular shape seems to fit for metal 
binding e.g. Cu (II) and Zn (II) (Morris et al. 2001ab, Houssen and Jaspars 
2010, Donia and Schmidt 2010). The metal binding propertyof these 
metabolites has not been shown to have a role in the ecology of L. patella and 
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Prochloron symbiosis, however, it has been reported in many studies 
(Houssen and Jaspars 2010). An increasing number of genome sequences 
has led to the discovery of a number of new ribosomal pathways in 
cyanobacteria and,  in many of  these,  the bioactivity or the ecological  role is  
unknown (Haft et al. 2010, Li et al. 2010, Wang et al. 2011, Tang and van der 
Donk 2012). 

1.6. Biosynthesis of cyanobactins 
 
Cyanobactins are made through PRPS (Post Ribosomal Peptide Synthesis) 
(Arnison et al. 2013). This means that a gene encoded precursor peptide is 
first transcribed. The precursor peptide is 50–150 amino acids long. The final 
peptide is modified and cleaved (Donia and Schmidt 2010, Sivonen et al. 
2010). Cleavage of the cyanobactin precursor peptide takes place at a 
minimum of two sites. A hypervariable amino acid core sequence inside these 
will ultimately form the cyanobactin (Figure 3) (Donia et al. 2006, Donia et 
al. 2008). In addition to the cleavage, the cyanobactin precursor is N-to-C 
macrocyclized and some of the amino acids can be modified (Donia and 
Schmidt 2010, Oman and van der Donk 2010, Sivonen et al. 2010). Generally 
the cysteines, threonines, and serines are heterocyclized to thiazolines and 
oxazolines, which can be oxidised to thiazoles and oxazoles (Figure 2). 
Occasionally  the  core  sequence  is  also  prenylated  (Figure  2)  (Donia  et  al.  
2008a, Donia and Schmidt 2011).  
 
 
Figure 3. Schematic figure of the cyanobactin gene cluster and the structure of the 
precursor peptide. The functions of the genes are shown. The genes B and C are essential, 
but the function is unknown. The cyanobactin structures are formed from the core region 
shown in the precursor peptide.  
 
1.6.1. Biosynthetic genes 
 
A  typical  set  of  genes  are  generally  present  in  the  cyanobactin  biosynthetic  
gene clusters (Figure 3). The gene cluster is approximately 10 kb and consists 
of the genes A-G, but the order of these genes can vary and cyanobactin gene 
clusters often encode an excess of additional short hypothetical proteins 
(Figure 4). The precursor gene is designated with the letter E. The 
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cyanobactin gene cluster encodes two protease genes, A and G (Donia and 
Schmidt 2010, Sivonen et al. 2010). These proteases are responsible for the 
cleavage of the precursor and N-to-C macrocyclization. The A-protease 
cleaves the N-terminal cleavage site of the core sequence and G-protease 
cleaves at the C-terminal cleavage site (Lee et al. 2009, Figure 2). The G-
protease has a macrocyclase domain which N-to-C cyclizes the cyanobactin. 
It can also have a domain which oxidises the heterocycles (Agarwal et al. 
2012, Koehnke et al. 2012). In a small number of cyanobactin gene clusters 
the oxidase is encoded in a separate gene (Sudek et al. 2008, Houssen et al. 
2012). Both the A and G proteases also have a domain of unknown function 
(Agarwal et al. 2012). The D-protein is a heterocyclase which modifies 
cysteines, serines, and threonines to heterocycles (McIntosh et al. 2010, 
McIntosh and Schmidt 2010). The cyanobactin gene clusters encode PatF, 
that in some cases, has been shown to prenylate the cyanobactins (Donia and 
Schmidt 2011, McIntosh et al. 2011). However, the patF-gene is also present 
in the non-prenylating pathways. Additionally, the cyanobactin gene clusters 
encode B and C genes, but these genes have no assigned function (Donia and 
Schmidt 2010, Sivonen et al. 2010).  
 
 
 
 
Figure 4. Cyanobactin gene clusters described in the literature. The length of the gene 
cluster is indicated. 
1
Donia and Schmidt 2011, 
2
Houssen  et  al.  2012,  
3
Sudek et al. 2006, 
4
Donia et al. 2008a, 
5
McIntosh et al. 2013, 
6
Ziemert et al. 2008b and 
7
Schmidt et al. 2005.  
 
1.6.2. Precursor peptide 
 
The precursor peptide is an essential component in the ribosomally 
synthesised and post-translationally modified peptides (Arnison et al. 2013). 
The  cyanobactin  structure  is  directly  encoded  in  the  precursor  peptide  and  
the core determines the amino acid backbone of the cyanobactin (Figure 5) 
(Donia  and  Schmidt  2010  and  Sivonen  et  al.  2010).  The  structure  and  the  
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sequence of the cyanobactin precursor peptide is conserved (Oman and van 
der Donk 2010, Houssen et al. 2010). The N-terminal part of the precursor 
peptide encodes a conserved leader sequence which is thought to be 
recognized by some of the modifying and cleaving enzymes (Houssen et al. 
2010). The sites surrounding the core sequence are recognition sequences 
(Oman and van der Donk 2010, Arnison et al. 2013) (Figure 5). The number 
of core sequences varies from one to four. In the tenuecyclamide (Donia et al. 
2008) and microcyclamide (Ziemert et al. 2008b) pathways, the precursor 
peptide has four cores in contrast to e.g. trichamide (Sudek et al. 2006), 
which has a single core sequence (Figure 5). The number of precursor genes 
varies  from  1  to  10.  Ten  precursor  genes  have  been  described  in  the  
cyanothecamide  biosynthetic  cluster  and  one  of  the  precursor  genes  is  
located on a plasmid (Houssen et al. 2012). Hence, there are two ways to 
enhance production of cyanobactins depending on the number of precursor 
genes or core sequences (Sivonen et al. 2010). The precursor peptide can be 
used for bioinformatic prediction of the cyanobactin product by aligning and 
comparison of the cleavage sites to known ones (Schmidt et al. 2005, Ziemert 
et al. 2008b, Donia et al 2008, Donia and Schmidt 2011). This information 
and knowledge of the enzymes carrying out post-translational modification 
in the biosynthetic pathway enables the prediction of the cyanobactin (Sudek 
et  al.  2006,  Ziemert  et  al.  2008b,  Schmidt  and  Donia  2011,  Houssen  et  al.  
2012).  
  
 
27 
        Fi
gu
re
 5
. A
 s
ch
em
at
ic
 fi
gu
re
 o
f a
 c
ya
no
ba
ct
in
 p
re
cu
rs
or
 p
ep
tid
e.
 T
h
e
 s
c
h
e
m
a
ti
c
 p
re
c
u
rs
o
r 
p
e
p
ti
d
e
 h
a
s 
fo
u
r 
c
o
re
 s
e
q
u
e
n
c
e
s 
(r
e
d
) 
a
n
d
 r
e
c
o
g
n
it
io
n
 s
e
q
u
e
n
ce
s 
(l
ig
h
t 
g
re
e
n
) 
su
rr
o
u
n
d
in
g
 t
h
e
 c
o
re
 s
e
q
u
e
n
c
e
s.
 C
o
rr
e
sp
o
n
d
in
g
 c
le
a
v
a
g
e
 s
it
e
s 
a
re
 s
h
o
w
n
 i
n
 t
h
e
 c
y
a
n
o
b
a
c
ti
n
 p
re
c
u
rs
o
r 
p
e
p
ti
d
e
 a
li
g
n
m
e
n
t 
b
e
lo
w
. 
T
h
e
 p
ro
d
u
c
in
g
 s
tr
a
in
 a
n
d
 
c
y
a
n
o
b
a
c
ti
n
 p
ro
d
u
c
t 
a
re
 s
h
o
w
n
. 
T
h
e
 c
le
a
v
a
g
e
 s
it
e
s 
a
re
 i
n
d
ic
a
te
d
 a
n
d
 t
h
e
 c
o
re
 s
e
q
u
e
n
c
e
s 
a
re
 h
ig
h
li
g
h
te
d
 w
it
h
 b
o
x
e
s.
 
     M.
 a
er
ug
in
os
a 
PC
C7
80
6 
mi
cr
oc
yc
la
mi
de
  
MD
KK
NL
LP
NQ
GA
PV
IR
GI
SG
KL
PS
HL
AE
LS
EE
AL
GG
NG
AE
AS
-A
TV
SI
C-
AF
DG
AE
AS
--
FT
GC
MC
-A
FD
GA
EA
S-
--
IT
GC
IC
-A
FD
GA
EA
S-
--
--
-I
TG
CI
C-
AF
DG
DE
A 
  
No
st
oc
 t
en
ue
cy
cl
am
id
e 
  
  
  
  
  
  
  
 M
DK
KN
IL
PQ
QG
KP
VI
RI
TT
GQ
LP
SF
LA
EL
SE
EA
LG
DA
GV
GA
S-
AT
GC
MC
-A
YD
GA
GA
S-
-A
TG
CM
C-
AY
DG
AG
AS
--
-A
TA
CA
C-
AY
DG
AG
AS
--
--
--
AT
AC
AC
-A
YE
  
 
L.
 a
es
tu
ar
ii
 P
CC
 8
10
6 
ae
st
ua
ra
mi
de
  
  
MD
KK
NI
LP
HQ
GK
PV
LR
TT
NG
KL
PS
HL
AE
LS
EE
AL
GG
NG
VD
AS
--
--
--
--
--
--
--
--
-A
CM
PC
YP
-S
YD
GV
DA
S-
-V
CM
PC
YP
-S
YD
GV
DA
S-
--
--
VC
MP
CY
P-
SY
DD
AE
  
 
M.
 a
er
ug
in
os
a 
NI
ES
29
8 
mi
cr
oc
yc
la
mi
de
  
MD
KK
NI
LP
QQ
GK
PV
FR
TT
TG
KL
PS
YL
AE
LS
EE
AL
GG
NG
LE
AS
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
HC
AT
IC
-A
FD
GA
EA
S-
--
--
-H
CA
TI
C-
AF
DG
DE
A 
Pr
oc
hl
or
on
 s
p.
 t
ru
nk
am
id
e 
  
  
  
  
  
  
MN
KK
NI
LP
QL
GQ
PV
IR
LT
AG
QL
SS
QL
AE
LS
EE
AL
GG
--
VD
AS
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
TL
PV
PT
LC
-S
YD
GV
DA
S-
--
--
-T
VP
TL
C-
SY
DD
 
Pr
oc
hl
or
on
 s
p.
 p
at
el
la
mi
de
  
  
  
  
  
  
MN
KK
NI
LP
QQ
GQ
PV
IR
LT
AG
QL
SS
QL
AE
LS
EE
AL
GD
AG
LE
AS
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
VT
AC
IT
FC
-A
YD
GV
EP
S-
--
-I
TV
CI
SV
C-
AY
DG
E 
T.
 e
ry
th
ra
eu
m 
IM
S1
01
 t
ri
ch
am
id
e 
  
  
  
MG
KK
NI
QP
NS
SQ
PV
FR
SL
VA
RP
AL
EE
LR
EE
NL
TE
GN
QG
HG
PL
AN
GP
GP
S-
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
GD
GL
HP
RL
CS
C-
SY
DG
DD
E 
A.
 p
la
te
ns
is
 N
IE
S3
9E
1 
ar
th
ro
sp
ir
am
id
e 
MD
KK
NI
TP
NP
QQ
PV
DR
VP
SG
QL
PS
AL
AE
LS
EE
AI
GS
LE
AL
P-
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
AG
RG
GL
PP
CV
C-
SY
DG
DD
E 
  
A.
 p
la
te
ns
is
 N
IE
S3
9E
2 
ar
th
ro
sp
ir
am
id
e 
MD
KK
NI
SP
NP
QQ
PV
DR
VP
SG
QL
PS
AL
AE
LS
EE
AI
GS
LA
LA
S-
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
GL
VL
MP
CF
C-
SY
EG
DD
E 
 
P.
 a
ga
rd
hi
i 
NI
ES
59
6 
pr
en
yl
ag
ar
am
id
e 
  
MT
KK
NL
KP
QQ
AA
PV
QR
EI
NT
TS
SE
AG
TG
LT
PL
RS
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
IG
DF
RH
P-
FA
GD
DA
E 
  
P.
 a
ga
rd
hi
i 
NI
ES
59
6 
pr
en
yl
ag
ar
am
id
e 
  
MT
KK
NL
KP
QQ
AA
PV
QR
EI
NT
TS
SE
SG
TS
TG
LT
PH
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
IN
PY
LY
P-
FA
GD
DA
E 
  
 
  
  
  
  
 L
e
a
d
e
r 
  
28 
 
 
1.6.3. Cyclization and cleavage 
 
The cyanobactin gene clusters encode two proteases which both contain 
subtilisin-like serine protease domains (Schmidt and Donia 2009). Lee et al. 
(2009) demonstrated in vitro that the PatG protease from the Prochloron 
patellamide pathway cleaves the C-terminal cleavage site and catalyses the 
macrocyclization of natural and artificial peptides (Lee et al. 2009). They also 
demonstrated that the Prochloron PatA-protease recognizes the N-terminal 
cleavage site of the precursor (Lee et al. 2009). The substrate tolerance of the 
PatG  protease  has  been  studied  with  synthetic  substrates  and  the  PatG  
protease from Prochloron was shown to macrocyclise a broad array of 
synthetic substrates even with non-proteinogenic and D-amino acids, but at a 
lower rate (McIntosh et al. 2010). Substrate peptides with 6 to 11 amino acids 
were circularized. The recognition site for the cleavage was shown to be 4 to 5 
amino acids (McIntosh et al. 2010). The crystal structure of the protease-
macrocyclase domain of the PatG from the patellamide and prenylagaramide 
pathway was studied and the catalytic triad Asp548, His618, and Ser783 was 
shown (Agarwal et al. 2012, Koehnke et al. 2012). The crystal structure of 
highly homologous protease domain of the PatA in the patellamide pathway 
has also been determined (Agarwal et al. 2012). In the macrocyclization 
process, first the PatA protease removes the amino terminal next to the core 
sequence to yield a free amino terminal, and the PatG protease removes the 
carboxy terminal sequence flanking the core (Agarwal et al. 2012, Koehnke et 
al. 2012). The cleavage site is protected by the PatG protease preventing 
access to water, stopping the hydrolysis until the transamidation reaction is 
complete (Agarwal et al. 2012, Koehnke et al. 2012). 
1.6.4. Heterocyclization 
 
The heterocyclase (D) was shown to catalyze the heterocyclization of 
cysteines, threonines, and serines to thiazolines or oxazolines (Donia and 
Schmidt  2010,  Sivonen  et  al.  2010).  Heterocyclase  D  has  been  described  in  
detail from the patellamide and trunkamide pathway (McIntosh and Schmidt 
2010). The pathways which encode the heterocyclase also encode an oxidase 
domain  fused  with  the  G-protease  or  standalone  oxidase  which  can  oxidise  
the oxazolines and thiazolines to oxazoles and thiazoles (Donia and Schmidt 
2010, Sivonen et al. 2010). It has been shown that the heterocyclase enzyme 
(D) alone is responsible for the hetrocyclization activity (McIntosh and 
Schmidt 2010). Heterocyclization was shown to take place before cleavage 
and macrocyclization for the precursor peptide as the heterocyclase enzyme 
needs the leader sequence to function in the patellamide and trunkamide 
pathway. The A-protease is capable of cleaving the unmodified precursor 
peptide before or after it is processed by heterocyclase but heterocyclization 
is dependent on the leader sequence (McIntosh and Schmidt 2010).  
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1.6.5. Prenylation 
 
The prenylation of cyanobactins is carried out by the prenyl transferase (F). 
Whilst the gene encoding the prenyl transferase is present in all cyanobactin 
gene clusters, only a few cyanobactins are actually prenylated (Schmidt and 
Donia 2009, Sivonen et al. 2010). Prenylating cyanobactin pathways include 
the prenylagaramide pathway in Planktothrix agardhii NIES 596 (Donia and 
Schmidt 2011), the aestuaramide pathway in Lyngbya aestuarii PCC 8106, 
and the trunkamide pathway in Prochloron (Donia et al. 2006). 
Prenylagaramide has O-prenylated tyrosine (Donia and Schmidt 2011), and 
in the trunkamide has O-prenylated threonine and serine (Donia et al. 2006). 
LynF prenyltransferase from Lyngbya aestuarii PCC 8106 has been studied 
in detail in vitro and it was shown to prenylate using dimethylallyl 
pyrophosphate (DMAPP) on the oxygen atom of tyrosine. This reverse O-
prenylated tyrosine undergoes spontaneous Claisen rearrangement yielding 
C-prenylated product (McIntosh et al. 2011). The cyanobactins in L. aestuarii 
PCC 8106 were already predicted in 2008 (Donia et al. 2008), but the 
cyanobactins were recently discovered and named aestuaramides (McIntosh 
et al. 2013). The structure was as predicted except for the oxidation level of 
the methionine and the form of the isoprenoid unit creating 12 variants from 
two core sequences (McIntosh et al. 2013). The oxidation of the methionine 
may be spontaneous and it may be increased during sample preparation, but 
the prenylation is made by LynF (McIntosh et al. 2011, McIntosh et al. 2013). 
In addition to unprenylated aestuaramides, two types of prenyls were found. 
It was shown that the aestuaramides are first reverse O-prenylated on 
tyrosine which can spontaneously undergo the Claisen reaction to C-prenyl 
as the in vitro studies had indicated (McIntosh eth al. 2011, McIntosh et al. 
2013). 
 
1.7. Analogous biosynthetic pathways in cyanobacteria 
 
In addition to cyanobactins, cyanobacteria produce other post-translationally 
modified  peptides  such  as  bacteriocins  and  microviridins  (Philmus  et  al.  
2008, Ziemert et al. 2008a, Li et al. 2010). Microviridins are tricyclic 
peptides cross-linked by ester and amide bonds processed from a precursor 
peptide (Philmus et al. 2008, Ziemert et al. 2008a). Bacteriocin biosynthetic 
genes seem to be very common in cyanobacteria (Wang et al. 2011, Shih et al. 
2013). The majority of cyanobacterial genomes were shown, in two distinct 
studies,  to  encode  bacteriocin  biosynthetic  genes  (Wang et  al.  2011,  Shih  et  
al. 2013). Cyanobacterial bacteriocins are described in detail in 
Prochlorococcus, which can produce up to 29 different bacteriocins (Li et al. 
2010,  Tang  and  van  der  Donk  2012).  In  the  prochlorosin  pathway  in  
Prochlorococcus,  a  single  enzyme  ProcM  modifies  the  29  linear  precursor  
peptides to highly variable polycyclic peptides with thioether cross-links of 
lanthionine and methyllanthionine (Tang and van der Donk 2012). Multiple 
bacteriocin biosynthetic gene clusters appear in one cyanobacterial genome. 
In a comparative analysis of 58 genomes, 145 bacteriocin gene clusters were 
found encoding  altogether  290 putative  bacteriocin  precursors  (Wang  et  al.  
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2011). Another bioinformatic study showed the wide distribution of 
bacteriocin pathways in different bacterial phyla and in that study 
cyanobactin pathways were included (Lee et al. 2008). An enormous variety 
of RiPPs such as bacteriocins, microcins, and lantibiotics are produced by 
other bacteria (Arnison et al. 2013). Most of these RiPPs have been 
extensively studied because of their interesting antimicrobial activities and 
all are derived from a precursor peptide that is post-translationally modified 
(Nolan and Walsh 2008, Arnison et al. 2013).  
 
Cyanobactins form a distinct group with shared and unique features in this 
enormous group of ribosomal natural products (Arnison et al. 2013). The 
unique feature of cyanobactins is in their biosynthesis. The precursor has 
multiple  cleavage  sites,  which  requires  two  proteases.  Shared  features  of  
cyanobactins include amino acid heterocyclization, oxidation of heterocycles, 
prenylation, methylation, and epimerisation. A classification scheme has 
been suggested for cyanobactins and it was based on corresponding 
genotypes and cyanobactin structure (Schmidt and Donia 2011). 
Cyanobactins have also been classified based strictly on the structure like 
bacteriocins (Cotter et al. 2013). In the bacteriocin classification, 
cyanobactins  are  suggested  to  be  divided  into  two  subsections  (Cotter  et  al.  
2013).  The  modified  cyanobactins  are  in  the  bacteriocin  class  I  of  modified  
bacteriocins including N-to-C-cyclic cyanobactins with heterocyclized or 
prenylated amino acids and the unmodified anacyclamides are in the group 
IIc of N-to-C-cyclic unmodified bacteriocins (Cotter et al. 2013). It is highly 
likely that new cyanobactins with novel post-translational modifications will 
be  found  in  the  future  and  the  classification  will  become  even  more  
complicated. 
 
1.8. Significance and biotechnological potential 
 
The significance of natural product discovery in inspiring synthetic organic 
chemistry to develop methods for production of novel products cannot be 
underestimated and this has an important role in drug development (Dunbar 
and Mitchell 2013). Cyclic peptides are known for their stability and 
resistance against proteases and therefore are considered to be desired 
candidates in drug design (Wipf 1995, Driggers et al. 2008, Cascales and 
Craik 2010, Velásques and van der Donk 2011, Thorstholm and Craik 2012). 
The biotechnological potential of the cyanobactin pathway lies in the 
macrocyclases and the precursor peptide guided biosynthesis (Agarwal et al. 
2012,  Koehnke  et  al.  2012,  Tianero  et  al.  2012).  The  core  sequence  of  the  
precursor peptide directly encodes the resulting cyanobactin and this 
sequence can be changed easily by genetic engineering in heterologous hosts 
and recombinant peptides can be produced (Donia et al. 2006, Tianero et al. 
2012). The enzymes in the cyanobactin pathway have very flexible substrate 
specificity for different amino acid sequences of the precursor peptide (Donia 
et  al.  2006,  Schmidt and Donia 2010,  Tianero et  al.  2012).  The trunkamide 
pathway has been utilized to produce the artificial compound eptidemnamide 
by replacing the precursor gene with an artificial precursor gene (Donia et al. 
2006). Each gene of the trunkamide gene cluster (patABCDFG) was cloned 
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independently to an expression vector in E. coli and co-expressed with the 
plasmid carrying the artificial precursor gene. The gene cluster, and the 
eptidemnamide encoded in the artificial precursor gene was expressed. The 
study proved the flexibility and utility of the pathways to produce designed 
peptides (Donia et al. 2006). The enzymes of natural product pathways can 
be utilized in a biotechnological approach to create novel compounds 
(Houssen and Jaspars 2010). The crystal structures of the proteases have 
been  examined  and  the  results  enable  studies  to  further  our  understanding  
and engineering systems that can efficiently produce cyclic peptides from 
linear precursor peptides (Agarwal et al. 2012, Koehnke et al. 2012). Bacterial 
expression systems have been developed but further research is  required to 
expand the catalytic potential and improve the production efficiency (Tianero 
et al. 2012). 
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2. Aims of the study 
 
The  aim of  this  study  was  to  explore  the  distribution  and  abundance  of  the  
cyanobactin pathway in cyanobacteria and to characterize the products of 
novel cyanobactin pathways based on genome mining in order to extend the 
known chemical diversity of cyanobactins. 
 
Specific aims of the present study were: 
 
- To  study  the  frequency  of  the  cyanobactin  pathway  and  evolution  of  
the protease gene (I) 
- To discover the product of an unknown cyanobactin pathway in 
Anabaena sp. 90 (II) 
- To discover the product of an inactive cyanobactin pathway in M. 
aeruginosa NIES 843 (III) 
- To study the frequency, distribution, and structure of cyanobactin 
pathways in cyanobacteria (IV) 
- To describe novel biosynthetic capacity and evolution of the 
cyanobactin pathway (IV) 
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3. Summary of materials and methods 
 
The materials and methods used in this study are listed in Table 4. Detailed 
descriptions  are  in  the  original  papers,  I-IV.  A  schematic  workflow  of  this  
study is shown in Figure 6. 
 
Table 4. The methods used in this study. Roman numerals refer to the article in which the 
method was used. 

Method Article 
Cultivation of cyanobacterial strains I-IV 
 -with stable isotopes 
14
N and 
34
S II-IV 
DNA extraction I-III 
Primer design I-III 
PCR amplification I-III 
Cloning II & III 
Analysing the transformants II & III 
Phylogenetic analyses I, II & IV 
Purification of aeruginosamides and NMR IV 
Sample preparation for LCMS II-IV 
Synthetic reference compounds II 
LCMS II-IV 
NMR IV 
High accuracy UPLC-ESI-QTOF mass spectrometry IV 
Bioinformatic analyses of gene clusters I-IV 
 
 
Figure 6. Schematic drawing of the workflow in studies I-IV.  
Cyanobacterial strains Cyanobacterial genome 
Screening 
cyanobactin genes 
by PCR (I–III) 
Screening cyanobactins by 
LCMS based on the presence 
of a prenyl unit (II &III) 
Bioinformatic analysis – 
characterizing cyanobactin 
genes (II-IV) 
Sequencing of the 
precursors genes (II-III) 
Prediction of 
cyanobactin 
structures (II–IV) 
LCMS – detecting the 
predicted cyanobactin 
structures and 
characterization of the 
cyanobactins (II–IV) 
Cultivation of the strains (with 
stable 
34
S and 
15
N) (II–IV) 
High accuracy UPLC-ESI-
QTOF (IV) 
NMR (IV) 
Comparison to synthetic 
compound (II) 
Expression of the 
cyanobactin gene cluster 
in a heterologous host  
 Proof of function (II, III) 
Structure of 
the 
cyanobactin 
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4. Summary of results and discussion 
 
4.1. Distribution of cyanobactin biosynthetic genes (I) 
 
A novel method to identify cyanobactin pathways was developed in this study 
(I). Usually, cyanobactins are found through genome mining or in the 
screening of potential bioactive compounds (Velásques and van der Donk 
2011, Donia and Schmidt 2010). In this study (I), distribution of the 
cyanobactin pathway was studied among planktonic bloom-forming 
cyanobacteria. A primer pair was designed to amplify the gene encoding PatA 
protease, which cleaves the precursor peptide at the N-terminal recognition 
site  (Lee  et  al.  2009).  The  primers  amplified  a  1.4  kb  section  of  the  patA 
gene.  The  gene  encoding  the  PatA  protease  was  found  in  48  of  the  132  
cyanobacterial strains studied. These cyanobacteria were taxonomically 
disparate and included unicellular, filamentous, and heterocyst-
differentiating cyanobacteria. The patA gene was especially common in 
planktonic cyanobacteria. The results suggested that the cyanobactin 
pathway is widespread and sporadically distributed in cyanobacteria and 
hinted at the potential chemical diversity of cyanobactins encoded in this 
pathway. Prior to this study, just a few cyanobactin biosynthetic pathways 
had been described and most of those were found in the symbiotic 
Prochloron and  marine  cyanobacteria  (Schmidt  et  al.  2005,  Donia  et  al.  
2006, Sudek et al. 2006, Donia et al. 2008, Ziemert et al. 2008b). To further 
explore the evolution of the PatA proteins, phylogenetic trees were 
constructed  from  the  PatA  protease  and  16S  rRNA  sequences  from  25  
cyanobacterial strains. The trees were incongruent and the topologies were 
supported by high bootstrap-values. This observation suggests that the 
cyanobactin gene cluster has been transferred from one cyanobacterium to 
another and the incongruence is a result of horizontal gene transfer, which is 
supported by the high sequence diversity in the protease genes. 
 
4.2. Anacyclamides – novel cyanobactins in the strains of 
Anabaena (II) 
 
Bioinformatic analyses of the draft genome of Anabaena sp. 90 identified a 
cyanobactin gene cluster encoding an unknown cyanobactin. The gene 
cluster was annotated, however the automatic annotation missed the 
precursor gene that was found by manually searching. The gene cluster was 
different from those described previously for cyanobactins (Schmidt et al. 
2005, Sudek et al. 2006, Ziemert et al. 2008b). Six genes were encoded 
similar to those found in other cyanobactin gene clusters (Figure 7); however, 
a heterocyclase responsible for the heterocyclization of serine, threonine and 
cysteine, was absent. The oxidase domain of the AcyG protease, responsible 
for the oxidation of thiazolines and oxazolines, was also absent. Based on 
these observations, it was obvious that there would be no heterocycles in 
these cyanobactins. In addition to this, the N-terminal cleavage site of the 
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precursor peptide was not conserved and the product could not be directly 
predicted.  
 
Cysteines  are  common  in  cyanobactins  (Schmidt  et  al.  2005,  Sudek  et  al.  
2006,  Ziemert  et  al.  2008b).  Therefore,  in  order  to  identify  the  product  of  
this pathway, the precursor genes of other Anabaena strains were sequenced. 
The aim here was to identify a strain that encoded cysteine in the core region 
of the precursor peptide and discover the product of the pathway in this 
strain using a sulphur stable isotope labelling strategy. Primers were 
designed to amplify precursor genes in related Anabaena strains by PCR. A 
total of 26 precursor genes were amplified and sequenced, however, none of 
these precursor genes encoded cysteine in the core region. Anabaena sp. 
SYKE844B encoded a precursor peptide with methionine in the putative core 
region. This strain was cultivated on Z8 culture medium with Mg34SO4 as the 
sole  sulphur  source.  A  methanol  extract  of  the  cells  was  analysed  by  LCMS 
and compared to the cell extract, which was cultivated with Mg32SO4. By 
comparison of sum mass spectra of all of the ions from the chromatograms of 
labelled  and  unlabelled  cell  extracts,  a  peak  was  found with  a  mass  shift  of  
two units, which results from the mass difference between 32S and 34S atoms. 
By the above method the cyanobactin in Anabaena sp. SYKE844B was found 
to be a cyclic heptapeptide, Lys-Ile-Gly-Ile-Met-His-Pro, containing only 
proteinogenic amino acids and was later named anacyclamide A7. The 
structure analysis was based on the product ion spectrum and was confirmed 
by comparison to synthetic anacyclamide A7. Based on this finding, the 
cleavage sites were identified and applied to other anacyclamide precursors, 
and anacyclamides were detected in other 26 other Anabaena strains, 
including anacyclamide A10 from Anabaena sp. 90 (Figure 7). Altogether 18 
anacyclamide variants were detected in 27 strains of Anabaena.  
 
The anacyclamides in these Anabaena strains were cyclic peptides from 7 to 
20 amino acids, containing only proteinogenic amino acids (Table 5). Some 
anacyclamides were prenylated, double prenylated or geranylated. The 
prenyl in a heteroatom is seen in the LCMS analysis as the neutral loss of 68 
mass units, and geranyl as the loss of 136 mass units. The diversity of 
different anacyclamides resulting from the sequence variation in the 
precursor  peptide  was  tremendous  and  just  one  amino  acid,  the  proline  at  
the C-terminus, was conserved. Characterization of anacyclamides was based 
primarily on the amino acid sequence of the core peptide, product ion 
analysis, and mass spectrometric and chromatographic comparison to 
synthetic anacyclamides. To confirm that the putative cyanobactin cluster in 
Anabaena sp. 90 is responsible for anacyclamide production, the acy gene 
cluster was amplified and cloned in Escherichia coli TOP10. The production 
of anacyclamide was detected by LCMS and this demonstrated that the acy 
genes are responsible for the anacyclamide production.  
 
The discovery of anacyclamides here broadened the definition of 
cyanobactins to include unmodified cyclic peptides, which can have 
prenylated or geranylated amino acids. Other cyclic cyanobacterial peptides 
with only proteinogenic amino acids are nonapeptide oscillacyclin in O. 
agardhii (Fuji et al. 2000), octapeptides microphycin in M. aeruginosa 
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(Gesner-Apter and Carmeli 2008), planktocyclin in P. agardhii (Baumann et 
al. 2007), and dodecapeptide kawaguchipeptin B (Ishida et al. 1997). The 
discovery of anacyclamide pathway indicated that these peptides could be 
considered as potential products of the cyanobactin pathway. Based on the 
results in this study prenylagaramides (Murakami et al. 1999) in P. agardhii 
NIES 596 were also predicted to be products of this pathway. Subsequently, 
the prenylagaramides were shown to be made by the cyanobactin 
biosynthetic pathway (Donia and Schmidt 2011).  
 
 
 

Figure 7. The biosynthetic pathway of anacyclamide in Anabaena sp. 90 and structure of 
anacyclamide A10. The genes in grey are ORFs encoding hypothetical proteins and the 
gene in yellow encodes a transposase. The cleavage sites in the AcyE precursor peptide are 
indicated with arrows. 
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Table 5. Cyanobactins discovered in this study (II-IV). The modified amino acid is indicated 
with one letter abbreviations of the amino acids if known in the modification column. 
Cyanobactin Core sequence 
 
 
 
 
 
Am
in
o 
ac
id
s 
Modifications  Strain 
Ar
tic
le
 
Anacyclamide A10 TSQIWGSPVP 10  Anabaena e.g. 90  II 
Anacyclamide B10 SSVIWGSPVP 10  Anabaena e.g. 
1TU31S9 
Anacyclamide C10 SAQWQNFGVP 10  Anabaena e. g. 299A 
Anacyclamide D10 NAHWQNFGVP 10  Anabaena 1TU44S9 
Anacyclamide E10 YAPLQNFGVP 10  Anabaena PH256 
Anacyclamide E10P YAPLQNFGVP 10 Y-prenyl Anabaena PH256 
Anacyclamide A11 DNWLGEWIGIP 11  Anabaena e.g. 
BIR260 
Anacyclamide A15 HAFIGYDQDPTGKYP 15  Anabaena 37 
Anacyclamide A15G HAFIGYDQDPTGKYP 15 Geranyl Anabaena 37  
Anacyclamide A7 RERFVYP 7  Anabaena 1TU39S8 
Anacyclamide F10P YSNKPSDFSP 10 Prenyl Anabaena 1TU32S11 
Anacyclamide A9P YDDKLNLSP 9 Y-Prenyl Anabaena 1TU33S10 
Anacyclamide A20P WGNGTGLDWKLLTGGISASP 20 Prenyl Anabaena 202A1 
Anacyclamide A20PP WGNGTGLDWKLLTGGISASP 20 2 Prenyls Anabaena 202A1 
Anacyclamide A8P HQPWHAAP 8 W-Prenyl Anabaena TR232 
Anacyclamide B8 FSPDWRAP 8  Anabaena SYKE816 
Anacyclamide C8 VIQHYLFP 8  Anabaena PH262 
Anacyclamide B7 LIGIMHP 7  Anabaena SYKE844B 
Piricyclamide MSGVDYYNP 
NEFMQTGSYSGP 
TFCDLATKQCYP 
WILLADGTRPKNAP 
9 
12 
12 
14 
Geranyl 
Geranyl  
SS-bridge 
 
Microcystis aeruginosa 
PCC 7005 
III 
Piricyclamide TLGCMNGTERCLGLP 15 SS-bridge Microcystis Izancya 
36 and 41 
Piricyclamide FAIFLLLP 
ILGEGEGWNYNP 
8 
12 
 
Prenyl 
Microcystis Izancya 
42 
Piricyclamide GTHLYTYTP 9 Y-prenyl Microcystis 
aeruginosa SYKE864 
Piricyclamide SQWGWRGLSDP 11  Microcystis 
aeruginosa SYKE764 
 
Aeruginosamide B 
Aeruginosamide C 
(LINEAR) 
FFPC 
FFPVC 
4 
5 
Methylated 
C-terminus 
and 
prenylated 
N-terminus 
Microcystis 
aeruginosa PCC 9432 
IV 
Viridisamide A 
(LINEAR) 
FIC 3 Methylated 
C-terminus 
and 
prenylated 
N-terminus 
Oscillatoria nigro-
viridis PCC 7112 

 
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4.3. Piricyclamides – novel cyanobactins in the strains of 
Microcystis (III) 
 
Bioinformatic examination of an inactive cyanobactin gene cluster in M. 
aeruginosa NIES 843 led to the discovery of an active functional gene cluster 
and a new group of cyanobactins, piricyclamides, in several strains of M. 
aeruginosa.  A  cyanobactin  cluster  was  identified  in  the  genome  of  M. 
aeruginosa NIES 843 (Donia and Schmidt 2011). The gene cluster was 19.7 
kb, and it encoded many small hypothetical proteins and a short precursor 
gene. Re-examination of the cluster demonstrated that there were two more 
precursor genes in the inactive gene cluster, in addition to the described 
precursors. The gene encoding the PirG protease had a frameshift mutation, 
and  the  gene  encoding  the  PirA  protease  had  two  insertion  elements  of  4.4  
and 2.4 kb each. The pir cluster encoded all the essential cyanobactin genes 
except for the PatD heterocyclase and the oxidase domain of the PatG 
protease.  This  indicated  that  the  active  cluster  would  produce  cyanobactins  
lacking heterocycles. The pir cluster encoded three precursor genes and the 
putative core regions of each could be recognised in an alignment of the 
precursor peptides together with known cyanobactin precursor peptides. 
Because this gene cluster was inactive, it was hypothesised that other strains 
of M. aeruginosa might encode an active counterpart.  
 
A  total  of  74  Microcystis strains  were  thus  screened  by  PCR  and  LCMS  to  
find active producers of these types of cyanobactins. The LCMS screening 
was based on detecting prenyl or geranyl units at heteroatoms. This is seen as 
a  neutral  loss  of  the  prenyl  unit  of  68  Da  (geranyl  unit  of  136  Da)  with  the  
conditions used in the ion source. The neutral losses of the prenyl of geranyl 
units  can  be  collected  from  all  the  recorded  MS  and  MS2 spectra resulting 
from  one  sample.  In  this  way  the  molecular  ions  which  carry  a  loosely  
attached prenyl or geranyl units can be located in the LCMS data. 
Cyanobactin candidates were detected in six strains by LCMS. In these 
strains, the precursor gene could also be amplified by PCR. The precursor 
genes were cloned and sequenced and putative cyanobactin predictions were 
made. Based on the predictions and LCMS analysis, including stable isotope 
labelling with 34S and 14N and derivatization experiments, novel cyanobactins 
were found and named as piricyclamides.  
 
Piricyclamides contained only proteinogenic amino acids and some had 
prenylated  or  geranylated  amino  acids  (Figure  8,  Table  5).  Three  of  the  
piricyclamide precursor peptide core sequences had a double cysteine 
pattern  in  the  cyanobactin  coding  region.  This  pattern  suggested  that  these  
piricyclamides could have a disulfide bridge. Labelling experiments with 
stable 34S isotope indicated the presence of these two cysteines in three of the 
piricyclamide precursor peptides. A disulfide bridge was also identified and 
the structure verified by reduction and cysteine specific 
carboxyamidomethylation  of  the  thiol  groups  (Neitz  et  al.  2011).  In  this  
method, the disulfide bridge is first reduced and the free thiols are 
carboxyamidomethylated. The disulphide bridge is seen as a shift of 116 Da of 
the  molecular  mass,  whilst  free  reduced  cysteine  would  shift  57  Da.  The  
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molecular  mass  of  piricyclamide  with  a  disulphide  bridge  was  seen  after  
treatment in the LCMS analysis with 116 Da higher molecular mass, verifying 
the presence of a disulphide bridge. 
 
 
 
 
 
 
 
Figure 8. The piricyclamides gene cluster from M. aeruginosa PCC 7005. The detected and 
characterized piricyclamide structures are shown (A-D). Piricyclamides (A) and (D) have a 
geranyl unit in one of the amino acid side chain hetero atoms. The genes in grey are ORFs 
encoding hypothetical proteins and the precursor genes are separated from the cluster 
with a black bar showing that more precursor genes are encoded in the genome but could 
not be connected to the gene cluster, suggesting they are encoded at different locations in 
the genome of this strain. 
 
In M. aeruginosa PCC  7005,  four  piricyclamides  were  found  based  on  the  
amino acid sequences of the precursor peptides and LCMS analyses (Figure 
8).  Two  of  the  piricyclamides  were  geranylated  and  one  had  a  disulfide  
bridge (Figure 8, Table 5). The piricyclamide gene cluster was almost entirely 
amplified and sequenced from M. aeruginosa PCC 7005 (Figure 8). The 
primers were designed based on the interrupted gene cluster in M. 
aeruginosa NIES  843  and  the  precursor  gene  sequences  obtained  from  M. 
aeruginosa PCC 7005. The gene cluster was cloned into E. coli to prove this 
cluster to be responsible for the production of piricyclamides. The gene 
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cluster  was  sequenced  and  shown  to  be  9.6  kb  in  length  and  much  more  
compact in comparison to the inactive gene cluster. The pir cluster encoded a 
similar set of cyanobactin biosynthetic genes as the inactive gene cluster in 
M. aeruginosa NIES  843.  The  LCMS  analysis  of  E. coli with the cloned 
piricyclamide gene cluster proved the functionality of the gene cluster but 
only one piricyclamide was detected. The cloned gene cluster lacked its own 
promoter and a few precursor genes. The only detected piricyclamide in E. 
coli was encoded in the precursor located in the middle of the pir gene 
cluster. The piricyclamide detected was TFCDLATKQCYP with a disulfide 
bridge. In addition, M. aeruginosa NIES  843,  which  carries  an  inactive  
cyanobactin pathway, was analysed with LCMS and no cyanobactins were 
detected.  
 
In this study, the active counterpart for the inactive cyanobactin pathway in 
M. aeruginosa NIES  843  was  described  and  it  was  shown  to  appear  in  
several strains of Microcystis. Di-sulfide bridges and double cysteine 
patterns  were  seen  in  the  piricyclamides  precursor  peptides,  suggesting  di-
sulfide  bridges.  Among  cyanobactins,  the  disulfide  bridge  is  a  rare  post-
translational modification as it appears in addition to piricyclamides only in 
ulithiacyclamides (Ireland and Scheuer 1980, Ireland et al. 1982, Williams et 
al. 1989, Fu et al. 1998). In other ribosomal peptides than cyanobactins, the 
disulfide bridge between two cysteines is more common and thought to 
stabilize the structure and make it more resistant to degradation (Arnison et 
al. 2013, McIntosh et al. 2009). 
 
The  diversity  of  piricyclamide  precursors  was  examined  in  a  natural  bloom 
sample from Lake Tuusulanjärvi.  A 16S rRNA clone library was constructed 
from the bloom sample and 97 % of the 16S rRNA genes sequenced could be 
attributed to the genus Aphanizomenon,  while  3  %  of  the  clones  were  
assigned to the genus Microcystis. A pirE precursor gene library was 
constructed from the same sample and 122 clones were sequenced. The 
length  of  the  core  sequence  varied  from  7  to  22  amino  acids  and  some  
showed the disulfide bridge pattern of cysteines, suggesting formation of a 
di-sulfide bridge. Extensive sequence variety was seen in the core region of 
the precursor peptides. Altogether 19 unique piricyclamide precursor 
peptides were found. Microviridins are another group of cyanobacterial 
ribosomal peptides. In comparison to the microviridin precursor gene library 
of 50 clones from a natural sample (Ziemert et al. 2010), the core sequence of 
microviridins had 7 invariable amino acids while in the piricyclamide amino 
acid sequence, the last proline is the only shared amino acid. This 
demonstrates the high sequence variation of piricyclamides and the flexibility 
of the pathway. The microviridin pathway has more restricted sequence 
diversity of the precursor peptides because the final structure is dependent 
on certain amino acids to obtain the cage-like structure (Ziemert et al. 2010). 
It seems that the piricyclamide pathway requires only the last amino acid of 
the core sequence to be a proline. 
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4.4. Genome mining of cyanobactin pathways (IV) 
 
The frequency and distribution of the cyanobactin pathway was studied at 
the phylum level and on a genome scale. The presence of cyanobactin 
proteases PatA and PatG homologues in 126 cyanobacterial genome drafts 
was determined. The gene content of the cyanobactin gene clusters was 
analysed.  In  the  set  of  126  cyanobacterial  genomes,  25  %  encoded  a  
cyanobactin pathway and 31 cyanobactin clusters were found (Figure 9) in 30 
genomes. The cyanobactin pathway was sporadically distributed but seemed 
to be more common in late-branching cyanobacteria (Figure 9). The pathway 
was common in Arthrospira, Oscillatoria, and Microcystis, but not present 
in any of  the Prochlorococcus or Synechococcus genomes (Figure 9). It has 
been speculated that the cyanobactin pathway is one of the major routes to 
small molecule diversity in cyanobacteria (Donia et al. 2008). The structural 
diversity of cyanobactins is constantly increasing (Arnison et al. 2013, 
Velásques and van der Donk 2011). However, the non-ribosomal and 
bacteriocin-type natural-product pathway appear to be more common than 
the cyanobactin pathway in cyanobacteria (Shih et al. 2013). Genome mining 
represents a starting point that shows the capacity of the genomes for 
production of ribosomal peptides.  
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Figure 9. Species tree of cyanobacterial genomes. The tree shows the distribution of the 
cyanobactin gene clusters. The maximum likelihood tree was constructed from 29 
concatenated, conserved phylogenetic marker proteins. Nodes supported with a bootstrap 
value of 70 % are indicated with a blue dot. The strains highlighted in green have a 
complete cyanobactin pathway and the product is described. In the strains highlighted in 
pink, the product of the cyanobactin pathway has not been described or it is unknown. The 
strains with interrupted pathway are indicated with a square.  
 
The gene content of the 31 cyanobactin pathways was typically patA-patG 
(Figure 10). The gene for the PatD heterocyclase and the oxidase domain of 
the PatG protease was absent from the clusters which encoded cyanobactins 
without heterocycles. The main difference between the gene clusters was the 
number of the short hypothetical proteins. Some clusters were very compact 
and others had many short hypothetical proteins making the clusters larger. 
Interrupted genes were found in the Nodularia spumigena CCY9414 
cyanobactin cluster, which does not encode a precursor gene and has a 
truncated patA gene, suggesting it to be inactive (Vo et al. 2013). In 
Cyanothece sp. PCC 7822, precursor genes could not be found. The 
cyanobactin gene cluster in Calothrix sp. PCC 7103 does not encode patB or 
patC, and Leptolyngbya sp. PCC 7376 does not encode patC or patD, even 
though there is an oxidase domain in patG. The cyanobactin gene cluster of 
Leptolyngbya sp. PCC 7375 did not encode a PatG homolog.  
 
Some of the clusters were located on separate contigs. The number of 
precursor genes varied from 1–10 (Figure 10) in all cyanobactin gene 
clusters. Typically the last amino acid of the core region was cysteine or 
proline which was seen in the alignment of precursor peptides, except for the 
precursors which did not have the conserved C-terminal cleavage site and 
unclear last amino acids. The N-terminal leader sequences were conserved 
and could be divided into two groups containing either the LAELSEE or 
APVQR motif. Usually the LAELSEE-type precursor peptides had cysteine as 
the last amino acid of the core and proline in the APVQR-type. The pathways 
with the LAELSEE-type precursors generally showed the genetic capacity to 
produce heterocycles (Houssen et al. 2010). The leader sequence is thought 
to be important for the modifying enzymes (Houssen et al. 2010) and the 
observed division of the precursor leader sequences supports this finding for 
the presence of heterocyclase. An alignment of precursor peptides made it 
possible to directly predict the end-product of many of the cyanobactin 
pathways.  
 
The precursor peptides which did not contain conserved cleavage sites, or 
where the cleavage sites were absent, made bioinformatic prediction of the 
product impossible. Calothrix sp. PCC 7103, Leptolyngbya sp. PCC 7376 and 
PCC 7375 gene clusters encoded novel types of precursor peptides, and the 
cyanobactins were impossible to predict. The putative core sequences in the 
precursor peptides of Calothrix sp. PCC 7103 had many cysteines, but the N-
terminal cleavage site was unclear. The putative precursor peptide in 
Leptolyngbya sp.  PCC  7376  and  PCC  7375  showed  no  similarity  to  other  
precursor peptides at the C-terminal cleavage site. The cyanobactins that are 
unknown at the moment are interesting because they might have novel 
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structures and properties. Few of the clusters encoded proteins novel to the 
cyanobactin pathway. Methyltransferases were encoded in Oscillatoria sp. 
PCC 10802, Cyanothece sp. PCC 7425, Cyanothece sp. PCC 7822, 
Microcystis aeruginosa PCC 9432, Oscillatoria nigro-viridis PCC  7112  and  
Leptolyngbya sp. PCC 7376. Occasionally the methyltransferase domain was 
fused to other cyanobactin genes encoding PatA, PatG, or PatF homologs 
(Figure 10).  
 
Often the studies on cyanobacterial genomes are not focused on the 
biosynthetic  pathways  of  natural  products  but  some genome articles  report  
them (e. g. Wang et al. 2012, Voß et al. 2013, Frangeul et al. 2008, Kaneko et 
al. 2007). In this study, 126 cyanobacterial genomes in the NCBI database 
were included in the bioinformatic analysis and a general view of the 
occurrence of cyanobactin pathways and the genetic potential for 
cyanobactin production was characterized. This allows further studies to 
focus on the detection and characterization of potential natural products 
encoded in the genomes. One strategy to find the product of the pathway is to 
predict  the  structure  of  the  compound based  on  the  biosynthetic  genes  and  
precursor peptide, and to screen the predicted structures. This strategy has 
been successfully used in addition to this study in for example characterizing 
the product of the trichamide (Sudek et al. 2006), aesturamide (Donia et al. 
2006, McIntosh et al. 2013), cyanothecamide (Donia and Schmidt 2011, 
Houssen et al. 2012) and arthrospiramide pathways (Donia and Schmidt 
2011). Compared to the total of cyanobactin-like structures characterized 
from cyanobacteria (Tables 1–3), the number of the described biosynthetic 
gene clusters is very small. In this study, novel cyanobactin gene clusters 
have been characterized. The diversity of the post-translational modifications 
in cyanobactins is restricted compared to all ribosomally synthesised post-
translationally modified peptides (Arnison et al. 2013), suggesting that more 
post-translational modifications await discovery in the cyanobactin family.  
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Figure 10. The 31 cyanobactin pathways found in the genomes of 126 cyanobacterial 
genomes. The end-product of the cyanobactin pathway is indicated where known.  
 
4.5. The discovery of linear cyanobactins (IV) 
 
An interesting gene encoding a bimodular protein with homology to 
methyltransferases and prenyltranferases (PatF) was found during the 
bioinformatic examination of the cyanobactin gene clusters from Microcystis 
aeruginosa PCC  9432,  Oscillatoria nigro-viridis PCC 7112, and 
Leptolyngbya sp. PCC 7376 suggesting new post-translational modifications. 
The cyanobactins in Leptolyngbya sp. PCC 7376 could not be predicted 
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based  on  the  precursor  peptide  because  there  was  no  conservation  of  the  
cleavage  sites  in  the  C-terminus.  However,  the  precursor  peptides  of  M. 
aeruginosa PCC 9432 and O. nigro-viridis PCC 7112 had conserved cleavage 
sites and the analysis suggested that the products of the cyanobactin pathway 
in these strains might be shorter than in the known cyanobactins. By aligning 
the M. aeruginosa PCC 9432 and O. nigro-viridis PCC 7112 precursor 
peptides  with  the  similar  known  multicore  precursors  of  microcyclamide  
(Ziemert et al. 2008b), patellamide, trunkamide, tenuecyclamide, and 
aestuaramide (Donia et al. 2008, McIntosh et al. 2013), these novel 
cyanobactins were predicted to be 3–5 amino acids. Predicted peptides in M. 
aeruginosa PCC  9432  were  a  tetrapeptide  Phe-Phe-Pro-Cys  and  a  
pentapeptide Phe-Phe-Pro-Val-Cys. In O. nigro-viridis PCC 7112 the 
predicted cyanobactin was a tripeptide Phe-Ile-Cys. Candidates 
corresponding to the predictions were found by LCMS. Unexpectedly, the 
cyanobactins seemed to be linear peptides with a prenylated N-terminus and 
methylated C-terminus. Stable isotope labelling experiments with 15N and 
34S, and high accuracy mass spectrometry supported this finding. Final 
confirmation of the pentapeptide Phe-Phe-Pro-Val-Cys structure from M. 
aeruginosa PCC  9432  was  carried  out  with  NMR.  This  conclusively  
demonstrated that the product of the cyanobactin pathway in this strain was 
a linear cyanobactin.  
 
The structure was very similar to a cytotoxic compound, aeruginosamide, 
found in a bloom of M. aeruginosa (Lawton  et  al.  1999).  Based  on  this  
similarity, the linear cyanobactins produced by M. aeruginosa PCC 9432 
were named aeruginosamides B and C. The original aeruginosamide (Lawton 
et al. 1999) was considered to be aeruginosamide A. Instead of one prenyl, 
aeruginosamide  A  contains  two  prenyls  on  the  N-terminus  and  the  core  
sequence was slightly different (Figure 11B-D). In all the aeruginosamides the 
last amino acid is a heterocyclized cysteine. The tripeptide in O. nigro-viridis 
PCC  7112  was  named  viridisamide  A  (Figure  11A).  The  structures  of  the  
aeruginosamide B and viridisamide A were characterized based on LCMS 
product ion analyses and high accuracy UPLC-ESI-QTOF mass spectrometry. 
The bioinformatic examinations of cyanobactin pathways led to the discovery 
of linear cyanobactins, thus expanding the catalytic potential of the 
cyanobactin pathway. 
 
When G-protease sequences were aligned, the comparison exposed the 
catalytic triad of the macrocyclase domain Asp-His- Ser (Agarwal et al. 2012, 
Koehnke et al. 2012). The aspartic acid is replaced by glutamic acid in G-
protease of the linear cyanobactin producing strains in M. aeruginosa PCC 
9432 and O. nigro-viridis PCC 7112, but histidine and serine are present. It 
can be speculated that the ability to macrocyclize the core peptide may be lost 
from these linear cyanobactin pathways. The G-protease is still needed, 
however, to act as a protease and the protease activity apparently remains 
since the precursor peptide requires cleavage at the C-terminus. 
Alternatively,  the  core  sequences  may  be  too  short  for  the  macrocyclase,  or  
mutations in the macrocyclase have only resulted in the loss of the ability to 
macrocyclize.  
 
  
47 
 
The N-to-C cyclic structure of peptides stabilises and protects the structure 
from degradation (Wipf 1995, Craik and Cascales 2010, Montalbán-López et 
al.  2012).  Most  of  the  cyanobactins  are  cyclic  but  linear  cyanobactins  were  
discovered  here  (Study  IV).  The  structure  suggests  that  the  function  of  the  
prenyl group is to protect the N-terminus and the C-terminus is protected by 
methylation, as end protection of free termini is not needed in N-to-C cyclic 
cyanobactins. Some highly modified linear peptides have been described 
from cyanobacteria (Van Wagoner et al. 2007). Modified peptides are usually 
thought to be nonribosomal but perhaps some of them are actually made by a 
ribosomal pathway. In addition to aeruginosamides, the linear peptides 
protected this way are rare, but there are those such as muscoride in Nostoc 
muscorum (Nagatsu et al. 1995) with the N-terminus prenylated and the C-
terminus O-prenylated, and virenamide in Diplosoma virens (Carrol  et  al.  
1996) with the N-terminus prenylated and a decarboxylated C-terminus. The 
discovery of linear cyanobactins suggests the pathway of these types of 
peptides is ribosomal.  
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Figure 11. Linear cyanobactins. (A) Viridisamide A, (B) aeruginosamide B (C), 
aeruginosamide  C,  and  (D)  aeruginosamide  A  (Lawton  et  al.  1999).  The  amino  acid  
sequence of the cyanobactin is shown with the mass to charge ratio of the protonated 
molecule. The N-prenylation and identical C-terminal methyl 1,3-thiazole-4-carboxylate 
structure are highlighted. Aeruginosamides C and D are reverse prenylated and the 
aeruginosamide A has a forward prenyl. The conformation of the prenyl in viridisamide is 
unclear. 
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4.6. Cyanobactins in the strains of M. aeruginosa (III and IV) 
 
Microcystis is an ecologically and environmentally significant, toxic, and 
bloom-forming cyanobacterium (Kaneko et al. 2007, Frangeul et al. 2008). 
In addition to toxins and a range of other bioactive compounds, strains of M. 
aeruginosa can produce three different types of cyanobactins, each of which 
exhibits pronounced chemical variation. The microcyclamide pathway was 
first described in M. aeruginosa NIES  298  and  PCC  7806  (Ziemert  et  al.  
2008b). Microcyclamides are cyclic hexapeptides and they contain 
heterocyclized  amino  acids  (Ishida  et  al.  2000,  Ziemert  et  al.  2008b).  A  
cryptic cyanobactin cluster interrupted by multiple hypothetical proteins and 
transposases  was  found  in  the  genome  of  M. aeruginosa NIES 843 (Donia 
and Schmidt 2011). By re-analysing the cluster from this strain, this study 
showed it to be inactive due to insertions and interruption (III). 
 
Piricyclamides are slightly different from the known Microcystis 
cyanobactins microcyclamides (Ziemert et al 2008). In piricyclamides, the 
amino acid content varied from 7–17 amino acids: occasionally 
piricyclamides were prenylated, geranylated, or had di-sulfide bridges. 
Phylogenetic analyses of concatenated A- and G-proteases were carried out 
to study how these two cyanobactin pathways in M. aeruginosa strains have 
evolved  (III).  The  analysis  showed  the  divergence  of  microcyclamide  and  
piricyclamide pathways. The piricyclamide pathway grouped with trichamide 
and anacyclamide pathways, and the microcyclamide pathway was grouped 
with  the  other  multicore  precursor  pathways,  such  as  the  patellamide  
(Schmidt  et  al.  2005),  aestuaramide  (Donia  et  al.  2008,  McIntosh  et  al.  
2013), and tenuecyclamide pathway (Donia et al. 2008).  
 
In article IV, a third type of cyanobactin in M. aeruginosa strains was 
reported. The M. aeruginosa PCC  9432  was  shown  to  produce  linear  
cyanobactins of four and five amino acids. To date, three types of cyanobactin 
pathways are described in the strains of Microcystis, two of which are 
described  in  this  study  (II  and  IV).  When  the  protease  sequences  from  the  
aeruginosamide pathway were taken into account in the phylogenetic 
analysis of concatenated proteases, the aeruginosamide proteases are 
grouped with the microcyclamide proteases. This was already anticipated 
because the precursor sequence homology of the aeruginosamide precursor 
peptides to microcyclamide precursor peptides. 
 
The cyanobactin diversity and frequency in the genus Microcystis is 
interesting. Nearly all strains of the genus Microcystis examined encoded 
cyanobactin genes. There are differences in the cyanobactin pathways in 
Microcystis. Piricyclamides are encoded in multiple precursor genes, while 
microcyclamides and aeruginosamides are encoded in single precursor genes 
with multiple core sequences. This suggests that the level of cyanobactin 
produced  may  be  enhanced  by  an  increase  in  the  copy  number  of  the  core  
sequence. Another difference with the piricyclamide gene clusters from the 
other Microcystis cyanobactin clusters was that the piricyclamide gene 
clusters had long intergenic regions and encoded many hypothetical proteins. 
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The other cyanobactin gene clusters were compact with short intergenic 
regions between genes and lacking the hypothetical proteins. In addition to 
the aeruginosamide pathway, the M. aeruginosa PCC 9432 genome encoded 
piricyclamide precursor genes and a pirF,  but  no  other  piricyclamide  genes  
were found. These precursor genes encoded similar piricyclamides detected 
in study III, but no piricyclamides were detected in this strain. This suggests 
that  the  pathway  is  inactive  and  piricyclamide  genes  in  the  genome  of  M. 
aeruginosa PCC 9432 are remnants of a functional gene cluster. In contrast 
M. aeruginosa PCC 9809 encoded two types of cyanobactin pathways; 
microcyclamide and piricyclamide pathway. However, the piricyclamide 
pathway was located in two separate contigs and the patA homolog was 
interrupted, suggesting it might be inactive. The piricyclamide pathways 
were,  in  many  cases,  fragmented  on  different  contigs.  The  number  of  
repetitive regions and plasticity is common in Microcystis genomes (Kaneko 
et al. 2007, Frangeul et al. 2008). This may lead to fragmented pathways on 
different contigs due to the difficult assembly of repeat rich regions.  
 
Microcystis strains appear to be a prolific source of cyanobactins. In addition 
to the preceding cyanobactins, several cyanobactin-like compounds are 
described in M. aeruginosa,  such  as  kawaguchipeptin  (Ishida  et  al.  1996,  
1997) and microphycin (Gesner-Apter and Carmeli 2008). Kawaguchipeptins 
are cyclic undecapeptides with proteinogenic amino acids and 
kawaguchipeptin A has a prenylated tryptophan fused to the amino acid 
backbone  (Ishida  et  al.  1996,  1997).  The  structures  suggest  that  these  
peptides are synthesised by the cyanobactin pathway. In addition, slightly 
different cyanobactin-like peptides have been characterized in Microcystis. 
Aeruginazoles consist of 12 to 17 amino acids with thiazoles (Raveh and 
Carmeli  2010,  Adiv  et  al.  2012).  Aeruginazoles  can  be  chlorinated  or  di-
chlorinated at tyrosine (Adiv et al. 2012). These peptides are thought to be 
made by the cyanobactin pathway (Raveh and Carmeli 2010, Adiv et al. 
2012), but no halogenases have been described from the cyanobactin 
pathways to date. 
 
 
4.7. Evolution of the cyanobactin pathway  
 
The evolution of the cyanobactin proteins was examined using phylogenetic 
analyses in articles I and IV. The incongruence of 16S rRNA phylogeny with 
the phylogeny of part of PatA homologues suggested the cyanobactin gene 
clusters are exchanged between cyanobacteria by horizontal gene transfer (I). 
This same conclusion could be made based on the phylogenetic tree 
constructed from the sequences of the concatenated PatA and PatG homologs 
found in the bioinformatic study (IV) (Figure 12). The amino acid sequences 
of precursor peptides imply rapid evolution. The core sequences of precursor 
peptides vary considerably more than the rest of the precursor peptide. By 
alteration of a single nucleic acid in the core region, the cyanobactin products 
may gain new properties. The cyanobactin pathway seems to be a system 
developed for production of rapidly evolving peptides. According to the 
Screening Hypothesis (Firn and Jones 2000, 2003) the ability to create 
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chemical diversity is valuable to the producer. The flexibility of the enzymes 
in cyanobactin biosynthesis (Donia et al. 2006, Schmidt and Donia 2010, 
Tianero et al. 2012) supports the Screening Hypothesis.  
 
The tree constructed from concatenated protease PatA and PatG sequences 
tree was strongly supported and it indicated that the pathways with 
multicore precursors formed a well-supported group, as the other pathways 
usually  encoded  multiple  precursors  with  single  core  (Figure  12).  This  
suggests that the single core precursor gene in multiple copies is an ancient 
feature and the multicore precursor gene in a single copy is a derived feature. 
Additionally, the pathways with the ability to heterocyclize amino acids were 
present throughout the tree, suggesting that this ability has been lost at least 
twice (Figure 12). This suggests that the inability to heterocyclize is derived 
feature  and  the  ability  to  heterocyclize  is  an  ancestral  feature.  The  
relationship of cyanobactins to other ribosomal peptides is unclear. 
Compared  to  the  numerous  ribosomal  peptides  (Arnison  et  al.  2013),  
cyanobactins have many similar genetic and structural features, but they 
have the distinct feature of requiring two proteases to process the precursor 
peptide. Questions remaining here include how this system evolved and what 
is the relationship other ribosomal peptides. Clearly the cyanobactin pathway 
is related to the pathways of other post-translationally modified peptides, but 
the missing link between these pathways is still to be found. 
 
 

Figure 12. A maximum-likelihood tree illustrating the relationship between cyanobactin 
gene clusters. The tree was constructed from a concatenation of the cyanobactin protease 
amino acid sequences (PatA and PatG). The strains highlighted with blue show the 
cyanobactin pathways which lack the ability to heterocyclize amino acids. The strains 
indicated with green encode precursor genes with multiple core regions. 
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5. Conclusions  
 
In this study, the frequency of the cyanobactin pathway has been described 
and shown to be widely but sporadically distributed in cyanobacteria. A PCR 
screening strategy was developed to find cyanobactin producing candidates. 
Horizontal gene transfer was demonstrated to be involved in the evolution of 
the cyanobactin pathway. This study has shown that in addition to 
Prochloron, the obligate symbiont of ascidians, the free-living cyanobacteria 
often have cyanobactin biosynthetic genes.  
 
Novel cyanobactin pathways were described in the strains of Anabaena and 
Microcystis. The novel cyanobactins were named anacyclamides and 
piricyclamides. These cyanobactins were cyclic with solely proteinogenic 
amino acids, with occasionally some prenylated or geranylated amino acids, 
and  rarely  disulfide  bridges  occurring  between  two  cysteines.  These  studies  
are the first and at the moment, only reports of the cyanobactin pathway 
producing unmodified cyanobactins, without heterocycles, consisting only of 
proteinogenic amino acids. These two families of cyanobactins have 
increased the length variation of cyanobactins. In these studies, a stable 
sulphur isotope labelling strategy was used and proven to be a useful method 
for locating cyanobactins and in LCMS data.  
 
The result of a phylum-level bioinformatic analysis showed that 126 
cyanobacterial genomes contained 31 cyanobactin pathways. Many of the 
pathways were new and contained novel genes and a new type of precursor 
peptides, suggesting the presence of novel cyanobactins. This information 
can be further utilized in the search of novel cyanobactins. This study focused 
on two pathways encoding a novel protein fusion of prenyltransferase and 
methyltransferase, encoded in the cyanobactin pathways of Microcystis 
aeruginosa PCC  9432  and  Oscillatoria nigro-viridis PCC 7112. In addition, 
these pathways had interesting precursor peptides, which enabled prediction 
of cyanobactins consisting putatively of only 3-5 amino acids. Surprisingly, 
extensive chemical analysis showed that these cyanobactins were linear and 
were named aeruginosamides B, C, and viridisamide A. This work presents 
the novel finding that a cyanobactin pathway produces linear cyanobactins. 
These novel 3 to 5 amino acid linear cyanobactins have ends protected with 
N-prenyl and C-methyl. These types of linear peptides are rare in 
cyanobacteria. The naming of aeruginosamides was based on a highly similar 
known compound aeruginosamide described from Microcystis bloom 
(Lawton et al. 1999). The findings also suggest that the aeruginosamide is a 
cyanobactin and made ribosomally. 
 
Many of the genomes examined were from Microcystis and this study has 
shown  the  capability  of  the  strains  of  this  genus  to  produce  three  types  of  
cyanobactins; microcyclamides, piricyclamides, and aeruginosamides. 
Phylogenetic analyses showed that the piricyclamide and microcyclamide 
pathways  are  divergent  and  the  aeruginosamide  pathway  is  more  closely  
related to the microcyclamide pathway than the piricyclamide pathway. The 
phylogenetic investigation of concatenated proteases from the genome study 
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showed that multicore precursor cyanobactin producers are clustered into 
one well-resolved clade. The other cyanobactin pathways generally have 
more than one precursor, each encoding one cyanobactin in single core. The 
ability to heterocyclize appears throughout the phylogenetic tree and it 
showed  that  the  ability  has  been  lost  at  least  twice.  The  analysis  suggested  
that  the  single  core  precursor  and  ability  to  heterocyclize  would  be  ancient  
capabilities and derived features would include being a multicore precursor 
and loss of heterocyclase activity.  
 
This study has redefined the genetic and chemical diversity of the 
cyanobactin family through genome mining and chemical analyses. Prior to 
this study, the distribution of cyanobactin pathways was not known and only 
a few pathways were described. In this study, the cyanobactin family is twice 
redefined: first to include cyanobactins consisting solely of unmodified 
amino  acids,  and  second,  linear  cyanobactins.  The  results  gained  in  this  
study have significantly influenced the cyanobactin field; demonstrating how 
novel natural products can be found with the combination of bioinformatics 
and chemical analyses. The rapidly expanding structural diversity of 
cyanobactins hints that novel post-translational modifications await 
discovery. The question still remaining is why cyanobactins are made. Future 
studies are needed to shed light on the ecology and purpose of these 
widespread cyanobacterial peptides. 
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